SACHS
ASSOCIATES

2nd Annual

Sachs Immuno-Oncology: BD&L and Investment Forum

3rd June 2016
Hyatt Chicago Magnificent Mile • USA

Conference Guide

www.sachsforum.com

SACHS ASSOCIATES

Sachs Associates are delighted to welcome you to the:

2ND ANNUAL

Sachs Immuno-Oncology: BD&L and Investment Forum

3rd June 2016 • Hyatt Chicago Magnificent Mile • USA

Sachs Associates, building upon it's many years of expertise in organizing premier partnering and investor meetings in Europe and the United States, is proud to welcome you to the **2nd Annual Sachs Immuno-Oncology: BD&L and Investment Forum being held on 3rd June 2016 at the Hyatt Chicago Magnificent Mile**. This forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment.

Sachs Associates would like to thank our sponsors and partners who have helped make this event possible.

General Information

- The registration desk is open from 8.00am on 3rd June although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.
- **One-to-one meetings**
  Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Request for Presentations

Please use the agenda to mark off presentations that you are interested in and email your request to silvia@sachsforum.com after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Events Diary

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com

SACHS ASSOCIATES

4th Annual
MedTech & Digital Health Forum
for Technology & Healthcare Innovation

26th September 2016 • Congress Center Basel • Switzerland

The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT, and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 200 delegates and 25 presenting companies plus demos.

16th Annual
Biotech in Europe Forum
For Global Partnering & Investment

27th – 28th September 2016 • Congress Center Basel • Switzerland

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's bio industry, this event will once again be covered by our regular media partners. We expect over **600 delegates** and **100 presenting companies**.

Speakers

Aaron Foster, *Senior Director, R&D,* **Bellicum Pharmaceuticals, Inc.**

Dr. Foster is Senior Director of Product Discovery at Bellicum Pharmaceuticals. He leads the gene-modified T cell therapy research group that is developing systems for controlling T cell behavior in vivo using molecular switches. He received his doctorate in Chemical Engineering from the University of Sydney and was an Assistant Professor at Baylor College of Medicine, at the Center for Cell and Gene Therapy (CAGT) prior to joining Bellicum.

Anne Altmeyer, *VP Business Development, Negotiations,* **Baxalta, Inc.**

Anne has about 20 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development.

Since September 2015, Anne Altmeyer is a Vice President Business Development & Licensing at Baxalta. In this capacity, Anne focuses on global transactions for Baxalta's three businesses: Oncology, Hematology, and Immunology. From 2004 to August 2015, Anne worked at Novartis. Most recently, she was Vice President, Business Development & Licensing in the Oncology Business Unit. In this capacity, her responsibilities were to in-license or acquire Oncology assets. She also oversaw the Companion Diagnostics Business Development group and managed several alliances. Before joining Business Development, Anne worked as a Project Leader in the Novartis' Project Management Group. There, she led multidisciplinary Project Teams through the generation and implementation of strategies for several compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager in various Therapeutic Areas at Merck & Co.

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, New York, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a MBA and a MPH from the University of Medicine and Dentistry of New Jersey/Rutgers University, USA.

Axel Hoos, *SVP, TA Head Oncology R&D, and Head, Immuno-Oncology,* **GlaxoSmithKline Plc**

Dr. Axel Hoos is Senior Vice President, Therapeutic Area (TA) Head for Oncology R&D and Head of Immuno-Oncology at GlaxoSmithKline Pharmaceuticals (GSK). In this role he leads the Oncology TA and builds the immuno-oncology portfolio of GSK across the modalities of antibodies, small molecules, bispecific molecules and cell & gene therapies, for which he directs discovery and development.

Dr. Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI).

His efforts in Medicines Development and Global Health focus on novel therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents. Through his leadership a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology.

Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.

Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.

Speakers

Bard Geesaman, *Oncology Impact Management and Chief Compliance Officer,* **MPM Capital**

Bard J. Geesaman, M.D., Ph.D. has been with MPM and associated portfolio companies since 2002. Bard serves as MPM's Chief Compliance Officer (CCO). He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Bard founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company's acquisition. After Catalyst, Bard joined Centagenetix, an MPM-founded company exploring the genetics of successful aging.

In 2006, Bard joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan. Bard is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Bard is passionate about innovation in health care, and in 2008 took a two year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation.

He received a B.S. in neuroscience from U.C. Berkeley followed by concurrent degrees from Harvard Medical School and M.I.T., with his Ph.D. work focused on systems and computational neurobiology. Bard finished his medical training by completing a three-year medical residency at Massachusetts General Hospital.

Barry Labinger, *CEO,* **Biothera Phramaceuticals, Inc.**

Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals, and Immunex. He most recently served as Executive Vice President and President, Biosciences Division, at Emergent BioSolutions Inc., where he was responsible for all aspects of product development, manufacturing, and commercialization, including the advancement of partnering initiatives. Mr. Labinger has an MBA degree from J.L. Kellogg Graduate School of Management and bachelor's degree in economics from Northwestern University.

Bernard Fox, *CEO,* **UbiVac**

Dr. Fox is an internationally recognized leader in immuno-oncology and co-founder and CEO of UbiVac. He has led or participated in a number of first-in-human studies, including DPV-001, UbiVac's lead agent, currently in a randomized, multicenter phase II trial for NSCLC. He served on the board of Directors of NeoPharm from 2004 to 2010, and is currently on the Board of Directors of the Oregon Bioscience Association. In 2011, Dr. Fox co-founded UbiVac-CMV, to develop cytomegalovirus vectors as vaccines for cancer. Dr. Fox served/serves on Advisory Boards for Argos, AstraZeneca, Bristol-Meyers Squibb, Cell Genesys, Dendreon, EMD Serono, Janssen/Johnson and Johnson, MannKind, Micromet, Novartis, PerkinElmer and Pfizer. In 2015, Dr. Fox received the Visionary/Legacy Award from the Society for Immunotherapy of Cancer (SITC).

Dr. Fox also holds the Harder Family Endowed Chair for Cancer Research, and is Chief of the Laboratory of Molecular and Tumor Immunology, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Health and Services. He is also a member and co-leader of the Tumor Immunology Panel for the Knight Cancer Institute and adjunct associate professor, Department of Molecular Microbiology and Immunology, Oregon Health and Science University.

Dr. Fox received his PhD from Wayne State University and his fellowship training was with Dr. Steven A. Rosenberg, at the National Cancer Institute, NIH. He has received funding from the National Cancer Institute, Department of Defense, Prostate Cancer Foundation and several other foundations. He has published more than 130 manuscripts and book chapters, served on review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia, and serves on editorial boards of seven scientific journals. Dr. Fox is past President of the Society for Immunotherapy of Cancer and is current Chair of the World Immunotherapy Council, a consortium of 22 national and international cancer immunotherapy organizations.

Speakers

Biren Amin, *Managing Director,* **Jefferies, LLC**

Biren Amin joined Jefferies in 2011 and is a Managing Director and Senior Research Analyst covering the U.S. biotechnology sector. Mr. Amin has over 12 years sell side experience as an equity research analyst which began at Prudential Securities. Prior to that he worked for five years in the competitive intelligence group at Aventis Pharmaceuticals (now Sanofi). Mr. Amin is a licensed pharmacist, and holds a B.S. in Pharmacy from University of Sciences at Philadelphia. He also holds an M.S. in Pharmacy from Arnold and Marie Schwartz College of Pharmacy, and an M.B.A. from New York University.

Birgit Schoeberl, *Head of Discovery Division,* **Merrimack Pharmaceuticals, Inc.**

Dr. Birgit Schoeberl leads early stage drug discovery and development programs as the Head of Discovery at Merrimack. She is an internationally recognized leader in the application of Systems Biology to biology and drug development. In her years at Merrimack, she has held leadership roles in the creation and development of many of Merrimack's clinical programs, most notably MM-121. Dr. Schoeberl was also one of the founding scientists of Silver Creek Pharmaceuticals, a majority owned subsidiary of Merrimack focused on the application of Systems Biology to regenerative medicine. She serves on Silver Creek's Scientific Advisory Board and as an observer on their Board of Directors. Dr. Schoeberl also serves as a reviewer for multiple peer-reviewed journals, including *Cell Systems, Science Signaling*, and *PLOS Computational Biology.* She joined Merrimack in 2003 after doing postdoctoral training at the Massachusetts Institute of Technology where she built some of the earliest computational models of signaling networks. Dr. Schoeberl earned her PhD in Systems Biology from the Max Planck Institute for Dynamics of Complex Technical Systems and a MS in chemical engineering from the University of Karlsruhe, both in Germany.

Boris Peaker, *Managing Director, Biotechnology Equity Research,* **Cowen Group**

Boris Peaker is a managing director and senior research analyst covering emerging growth biotechnology companies. Prior to re-joining Cowen in 2014, Dr. Peaker was a senior analyst at Oppenheimer & Co. and Rodman & Renshaw, covering large-, mid-, and small-cap biotechnology stocks. Dr. Peaker holds a BS in physics and chemistry from Stony Brook University and a Ph.D. in biophysics from Stanford University. He is a CFA charterholder.

Brad Loncar, *Chief Executive Officer,* **Loncar Investment, LLC**

Brad Loncar is an independent biotechnology investor and Chief Executive Officer of Loncar Investments, LLC. In 2015, the Loncar Cancer Immunotherapy ETF (CNCR) launched on the NASDAQ stock market. Mr. Loncar incorporates his extensive research into biotech companies and technologies to develop indexes focused on precise investment opportunities. He previously worked in the financial services industry at Franklin Templeton Investments, and was appointed to serve in a Senior Adviser role at the U.S. Department of the Treasury.

Speakers

Deborah Morosini, *VP Patient Engagement & Clinical Trials,* **LOXO Oncology, Inc.**

Dr. Deborah Morosini joined LOXO Oncology in 2016 as vice president of clinical affairs & patient engagement, bringing expertise in oncology drug development, clinical genomics and insightful philanthropic activism. As an early team member at Foundation Medicine (FMI), she developed a niche specialty in the genomics of adolescent and young adult (AYA) cancer. Prior to joining FMI, she founded and led the molecular pathology group at AstraZeneca Pharmaceuticals (AZ), where she helped develop and implement biomarker strategies for biomarker driven trials. Prior to AZ, she served as director of pathology for Ardais, a clinical genomics biotechnology company.

Inspired by her late sister and brother in law, Christopher and Dana Reeve, Deborah is a seasoned keynote speaker and patient advocate. As a featured spokesperson for numerous non-profit and government events in oncology she has provided expert commentary for national broadcase media.

Deborah earned her BA in English from Mount Holyoke College and her MSW from NYU Graduate School of Social Work. After completing post BA pre-medical studies at Columbia University, she received her MD from Boston University School of Medicine and completed a pathology residency at Boston Medical Center, where she was chief resident. She currently serves on the Board of Directors for the National Comprehensive Cancer Network (NCCN) Foundation, the Bonnie J. Addario Lung Cancer Foundation, the National Patient Advocate Foundation (NPAF) scientific advisory board, Target Cancer, the NHGRI council, Cancer Support Community: central New Jersey, and the development subcommittee for the AYA cancer foundation, Critical Mass.

Feran Prat, *Vice President, Strategic Industry Ventures,* **MD Anderson Cancer Center**

Ferran Prat helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. He is responsible for establishing a direct line of contact with pharmaceutical companies to understand their needs in terms of pre-clinical and Phase 1 activities, and internally convey them so that the researchers and clinicians at MD Anderson can follow-up and establish personal relationships with such companies.

Prior to joining MD Anderson he worked at Alere Inc., an international firm dedicated to developing health management services and solutions, including diagnostic tools and tests. At Alere, Ferran led a business turnaround and integrated three businesses in São Paulo and Belo Horizonte, Brazil. He also served as the head of the Oncology and Women's Health Divisions in San Diego, where he was responsible for all pre-commercialization activities and post-launch product management.

Prior to Alere, Ferran held a number of industry and academic positions, including vice president for licensing at Biosite Inc., management consultant at McKinsey & Co., engineer at Chromogenia-Units and researcher at the University of California – Los Angeles. In these roles, he in-licensed and out-licensed new technologies, led and executed strategic plans, coordinated intellectual property agreements among private and public sector entities, and conducted basic science research that led to multiple peer-reviewed articles.

Prat has a Ph.D. in organic chemistry from the University of California – Los Angeles and a J.D. from the University of San Diego School of Law.

Speakers

Francis Kern, *Senior Director, External Scientific Affairs,* **Daiichi Sankyo, Inc.**

Dr. Kern is currently Senior Director of External Scientific Affairs at Daiichi Sankyo where he leads the U.S. group responsible for identifying and evaluating in-licensing, partnering, and external research collaboration opportunities in Oncology. In his previous position as Scientific Officer and Head of Program Development for Oncology at the Adelson Medical Research Foundation, he developed a portfolio of collaborative and interactive translational research programs in ovarian cancer, melanoma, lymphoma and lung cancer involving key opinion leaders at major academic research and Cancer Centers throughout the U.S., Europe, Australia and Israel. Prior to that, as Senior Director of Oncology at Lexicon Genetics, he implemented novel approaches to oncology drug target identification and validation and was charged with advancing targeted anticancer therapeutics. The academic portion of his career primarily involved establishing and directing a basic and translational research program on molecular and cellular mechanisms underlying breast cancer progression to antiestrogen-resistant and metastatic phenotypes. He began this program first as a Senior Staff Fellow in the Breast Cancer Section of the Medicine Branch of the National Cancer Institute and subsequently as a faculty member at the Lombardi Cancer at Georgetown University and as Director and Department Head of Biochemistry and Molecular Biology at the Southern Research Institute in Birmingham, Alabama where he also held the Adolph Weil Endowed Chair in Cancer Biology. While there, he also had program and executive oversight leadership roles within the University of Alabama at Birmingham's NIH-Designated Comprehensive Cancer Center as co-leader of their Women's Cancer Program. He received his bachelor's degree in Biological Sciences from Rutgers College and his Ph.D. in Microbiology from Rutgers University and his postdoctoral training in Cellular and Molecular Biology at the NYU Medical Center.

Francois Lebel, *Executive Vice President, Research and Development, Chief Medical Officer,* **ZIOPHARM Oncology, Inc.**

Francois is a drug developer who has provided strategic leadership on 8 NDA/BLA's and a number of mergers and acquisitions. Past senior leadership roles have included Vice President, R&D at Baxter International and Global Head of Medical and Scientific Affairs at MedImmune. He has extensive global experience in drug development, Translational Medicine, Medical and Regulatory Affairs, Drug Safety and Pharmacovigilance acquired through various roles of increasing responsibilities at Chiron (Novartis), Warner-Lambert (Pfizer) and Burroughs Wellcome (GSK). He has led numerous pre-clinical programs and phase I-IV trials with biologics including gene therapy; small molecules and drug devices combinations. Currently he oversees multiple gene therapy trials using an adenoviral vector, CAR-T and NK cells. Francois received his medical degree from the University of Ottawa, Canada. He is Board Certified in Internal Medicine, and an Infectious Diseases specialist trained at McGill University and Harvard Medical School. He is a Fellow of the Royal College of Medicine (C) and was a Research Fellow in immuno-virology at the Massachusetts General Hospital.

Speakers

Frank Jones, *Chairman, Founder, Chief Executive Officer and Chief Scientific Officer,* **Etubics Corporation**

Dr. Frank Jones is a seasoned biotech entrepreneur. As the founder of Etubics Corporation ("Etubics" or the "Company"), he has served as the Company's Chairman of the Board of Director's and Chief Executive Officer since its inception. Etubics Corporation is a next generation clinical stage bio-pharmaceutical company which has developed a proprietary platform technology consisting of the Adenovirus Vector Vaccine Platform and the proprietary manufacturing E.C7 human cell line, collectively, the "Etubics Platform". The Company develops immunotherapies and vaccines with a focus on treatment of cancer and infectious diseases. The Company commenced operations in 2006 and is based in Seattle, Washington. Dr. Jones is the Principal Investigator on most of the Company's NIH grants and contracts with a combined value of over $19 million. Dr. Jones also serves as the Chief Scientific Officer of Etubics. In 2016, Etubics announced its participation in the National Immunotherapy Coalition and the Cancer MoonShot 2020 program, which program focuses on designing, initiating and completing randomized clinical trials at all stages of cancer in as many as 20,000 patients by the end of the year 2020. In January, 2016, Etubics completed a merger transaction pursuant to which the Company merged with and into NantCell, a biopharmaceutical company focused on the discovery of innovative molecularly targeted therapies based on the unique molecular profile of the patient's tumor, independent of the cancer's anatomical type, which was founded and operated by Dr. Patrick Soon-Shiong. Etubics continues to focus on research and development of numerous immunotherapeutic vaccines and other immunotherapies and works with NantCell and other entities owned and operated by Dr. Soon-Shiong in connection with pursuing various initiatives in the Cancer MoonShot 2020 program.

From 1981 to 1996, Dr. Jones served as Founding Chairman and Chief Executive Officer of the publicly traded, fully integrated, medical device company, IMRÉ Corporation. IMRÉ focused on immunoadsorption treatments for various human diseases including rheumatoid arthritis and certain cancers. He raised over $100 million through private and three public offerings. Dr. Jones directed the Company through the start-up phase, technology development, pre-clinical studies, GMP production of its own products, preparation of patent applications for product and treatment protection, clinical trials, preparation and submission of IDE's, submission of PMA, and submission of post market approval data and documents to the FDA. He did the basic research for the Company's products. He was the standard bearer for the Company in the Investment Banking and finance arena as well as the scientific world.

From 1996 to 1998, Dr. Jones was Chairman and Chief Executive Officer of Scius Corporation, a private computer technology company which developed applications to manage and operate stirred tank manufacturing products. From 1998 to 2003 he was a consultant to the biotechnology industry and was the Managing Partner of Haidas Ranches, LLC, a land development company. From 1983 until 1986, Dr. Jones was Director of the Immune Response Program of the Pacific Northwest Research Foundation in Seattle. Dr. Jones was a Researcher in the Department of Complement and Effector Biology at Memorial Sloan Kettering Cancer Center ("MSKCC") in New York City from 1980 to 1981 and was a Research Associate in the Laboratory of Veterinary Oncology at MSKCC from 1981 to 1983. He developed a treatment for feline leukemia virus and was the first to publish the reversal of a retrovirus.

Dr. Jones is member of the American Society of Clinical Oncology, American Association for Cancer Research and the Society for Immunotherapy of Cancer. He holds a Ph.D. degree from the University of Washington in Biological Structure/Cellular Immunology. He has 12 patents to his name and has published over 50 peer reviewed scientific papers. He has presented various business and scientific presentations on a national and international basis.

Gary Sclar, *Chief Research Business Development Officer,* **Dana-Farber Cancer Institute**

Gary Sclar is the Vice President, Dana-Farber Innovation at the Dana-Farber Cancer Institute. He is responsible for business development, licensing and alliance management strategies and solutions and has deep experience with immuno-oncology strategic initiatives and partnerships. Before joining the Dana-Farber, Gary held the position of Chief Strategy Officer for MedMetrics Health Partners and Public Sector Partners. Gary has over 15 years of technology licensing experience, having worked in the technology licensing offices of Northeastern University, Brigham and Women's Hospital, and the University of Massachusetts Medical School. Prior, Gary directed laboratories at Washington University School of Medicine and The Jackson Laboratory, specializing in nuclear transplantation and the generation of transgenic and embryonic stem cell knock-out animals. Gary has a Bachelor of Science degree from the University of Massachusetts, a Masters degree from Webster University School of Business, and a JD degree from Massachusetts School of Law. He is admitted to the Massachusetts Bar and United States District Court in Massachusetts.

Speakers

Gregory Frost, *Managing Director,* **F1 BioVentures**

Dr. Frost has been Managing Director of F1 BioVentures, LLC since 2015. Previously, he led the Health Sector of Intrexon Corporation, a multinational public biotechnology company, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics, a San Diego public biotechnology company he co-founded that focused on oncology biologics and medication delivery. At Halozyme he served on the Board of Directors and in numerous operational roles including Chief Scientific Officer since 2002, and CEO since 2010. He has authored multiple peer-reviewed and invited scientific articles, and is an inventor on key patents supporting a number of FDA approved biologics. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz, his Ph.D. in the Department of Pathology at the University of California, San Francisco, and performed postdoctoral research at the Sidney Kimmel Cancer Center. As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyme and secured initial financing for the company. In 2012, Dr. Frost was named by Forbes as one of Americas 20 most powerful CEO's under 40. Dr. Frost additionally serves on the board of BioCom, a member-driven organization serving the life science community of Southern California and BioAtla, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics.

Guillaume Vignon, *Head of Immuno-Oncology Licensing & Business Development,* **EMD Serono**

Guillaume Vignon is the Head of Immuno-Oncology Licensing & Business Development at EMD Serono, responsible for leading partnering activities in the field of Immuno-Oncology, from evaluation stage till deal closure.

Throughout his career at Merck, Guillaume has held numerous positions of increasing responsibility within Global Licensing & Business Development and has played a key role in successfully closing complex transactions and forging key partnerships in the fields of Oncology, Immuno-Oncology, Companion Diagnostic, and Antibody Discovery.

Guillaume Vignon holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France and an MBA from Hult International Business School, Cambridge, USA.

Helen Tayton-Martin, *Chief Operating Officer,* **Adaptimmune, LLC**

Dr. Helen Tayton-Martin has served as Adaptimmune's Chief Operating Officer since July 2008 and is one of its co-founders. She is responsible for business development and commercial activities, including our strategic partnership with GSK.

Dr. Tayton-Martin has 23 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She is a co-founder of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy from 2005 to 2008. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

Speakers

Henry Gosebruch, *Executive Vice President and Chief Strategy Officer,* **AbbVie, Inc.**

Henry Gosebruch is Executive Vice President and Chief Strategy Officer at AbbVie, a global pharmaceutical company employing approximately 28,000 people and marketing medicines in more than 170 countries. As a member of AbbVie's Executive Leadership Team, he is responsible for Corporate Strategic Planning, Licensing and Acquisitions, Alliance Management, Venture Capital Investments, and Early Stage Collaborations. Henry's focus is to continue the advancement of AbbVie's corporate strategy and to identify external opportunities to complement AbbVie's internal innovation with partnered innovation in order to bring a consistent stream of innovative new medicines to patients worldwide.

Henry joined AbbVie in 2015. Prior to his AbbVie appointment, Henry was Co-Head of J.P. Morgan's North American Mergers & Acquisitions Group based in New York. He was a member of J.P. Morgan's M&A group for more than 20 years where he worked on announced M&A transactions in excess of $375 billion in total value involving companies in more than 20 countries. Henry is a frequent speaker on M&A panels and has been quoted by or appeared in articles by Bloomberg, CFO Magazine, the Financial Times and the New York Times. He has also been a faculty member of the Pli (Practising Law Institute) regarding M&A since 2010. In October 2007 he was selected by the New York Times for its Face Book of Wall Street's Future listing 100 bankers, lawyers and investors.

Henry graduated from the Wharton School at the University of Pennsylvania in 1995. He is a member of the advisory board for the Life Sciences & Management Program at the University of Pennsylvania.

Howard Fingert, *Senior Medical Director, Internal and External Innovation for Oncology,*
Takeda Pharmaceuticals International GmbH

Howard Fingert, M.D, is Senior Medical Director, Internal and External Innovation for Takeda Oncology, managing global public-private partnerships.. At Pfizer and other biotech/pharma companies, he has over 20 years experience managing licensing, M&A, and clinical programs with small molecules and immune-oncology products developed for diverse adult and pediatric indications. He also had prior academic faculty positions at Harvard and Tufts medical schools with published experience in cancer biomarkers, pharmacology, drug safety, phases 1-4 clinical trials, and regulatory sciences. He currently serves on the AACR Subcommittee for Regulatory Science and Policy, and he recently served as the Industry Representative to the FDA Oncology Drugs Advisory Committee.

Speakers

James Allison, *Chairman, Department of Immunology, Director, Immunology Platform,*
MD Anderson Cancer Center

James Allison was born in Alice, Texas. He obtained his B.S. (1969) and Ph.D. (1973) from The University of Texas at Austin. After a postdoctoral fellowship at Scripps Clinic and Research Foundation he joined the faculty of The University of Texas MD Anderson Cancer Center Science Park in Smithville, Texas, in 1974 as Assistant Biochemist. He moved to the University of California, Berkeley in 1984 as Professor of Immunology. At Berkeley he served as Director of the Cancer Research Laboratory, Head of the Division of Immunology in the Department of Molecular and Cell Biology, and Co-chair of the Department of Molecular and Cell Biology. In 2004 he moved to the Memorial Sloan Kettering Cancer Center in New York City, where he was Professor of Immunology, Chair of Immunology and Director of the Ludwig Center for Cancer Immunotherapy. In 2012 he moved to The University of Texas MD Anderson Cancer Center, where he is Professor of Immunology, Chair of the Department of Immunology, and Executive Director of the Immunotherapy Platform.

Allison's fundamental discoveries include the definition of the structure of the T cell antigen receptor, demonstration that the T cell molecule CD28 provides costimulatory signals necessary for full T cells activation, and identification of the inhibitory checkpoint molecule CTLA-4, which inhibits activated T cells. He proposed that immune checkpoint blockade might be a powerful strategy for therapy of many cancer types, and conducted preclinical experiments showing its potential. He was involved in the development of Ipilimumab, which was approved by the FDA for treatment of metastatic melanoma in 2011. In 2014, the FDA approved two antibodies to PD-1, a related immune checkpoint, for the treatment of melanoma. In 2015 the FDA approved five additional CTLA-4 and PD-1 antibodies and combinations of both for the treatment of a variety of additional indications, including melanoma, lung, and kidney cancer. Allison's development of immune checkpoint blockade transformed cancer therapy and has been responsible for saving the lives of thousands of cancer patients.

Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine. In 1997 he was appointed as an Investigator of the Howard Hughes Medical Institute, a position that he held until his move to MD Anderson. He has received numerous national and international awards, including the Lifetime Achievement Award from the American Association of Immunologists, the Lloyd J. Old Award from the American Association for Cancer Research, the Novartis Award for Clinical Immunology, the Economist Magazine Innovation Prize for Biomedicine, the Breakthrough Prize in Bioscience, the Szent-Gyorgyi Prize for Progress in Cancer Research, the first Tang Prize for Biopharmaceutical Science, the Canada Gairdner International Award, the Louisa Gross Horwitz Prize, the Giants of Cancer Care Award in Scientific Advances, the Harvey Prize in Human Health, the AACR/Pezcoller International Award for Cancer Research, and the ASCO Science of Oncology Award. In 2015 he received the Lasker-DeBakey Clinical Medical Research Award.

James Mulé, *Associate Center Director for Translational Research,*
H. Lee Moffitt Cancer Center & Research Institute

Dr. Mulé is the Associate Center Director for Translational Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida.

Dr. Mulé, who was recently designated a "Master of Immunology" by the American Association for Cancer Research, is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in solid tumors. His clinical research group is involved in developing and validating genomic signatures of immunotherapy response, as well as vaccine strategies (e.g., with dendritic cells) and other approaches (e.g., with adoptive T cells) to recognize and destroy tumors. The translational work in these areas has helped to develop new treatments for advanced cancer patients.

Dr. Mulé serves on Advisory Boards of numerous biotechnology and pharma companies (e.g., OncoPep, Lion Biotech, Oxis, Vault Nano, Celgene, among others). He remains a long-standing special government employee to the FDA (CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director's Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). He has published nearly 200 articles in the areas of cancer vaccines and adoptive immunotherapy, and is a continuously funded investigator for nearly 25 years.

Dr. Mulé received a special individual Ph.D. (IPh.D.) degree in Tumor Immunology from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Alto, CA, where he helped to launch and scientifically direct two biotechnology companies. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endowed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.

Speakers

Jeff Wiezorek, *Senior Vice President, Clinical Development,* **Kite Pharma, Inc.**

Dr. Wiezorek served as Executive Medical Director, Global Development, at Amgen. In this position, he was responsible for global oversight of the clinical strategy for the immunotherapy (including blinatumomab and talimogene laherparepvec), angiogenesis, and denosumab oncology product areas. Previously, he was Amgen's Global Development Leader for multiple programs encompassing phase one through phase four trials. In these roles, Dr. Wiezorek worked closely with global regulatory agencies, and he was the development lead for the approval of Vectibix in combination with chemotherapy in Europe. Prior to joining Amgen, he investigated the role of nuclear factor-kappaß in cellular proliferation and cancer pathogenesis in the laboratory of Dr. David Baltimore at the California Institute of Technology. Dr. Wiezorek is author or co-author on more than 30 peer-reviewed articles and presentation abstracts. He received his B.A. degree in biophysics from the University of Pennsylvania and his M.D. degree from Columbia University, trained in internal medicine at Stanford University and completed a fellowship in oncology at the University of California, Los Angeles.

Ji Li, *Executive Vice President, Global Head of Business Development,* **BeiGene Ltd.**

Dr. Ji Li is currently Executive Vice President and Global Head of Business Development at BeiGene where he oversees the company's overall partnering activities. Prior to BeiGene, Dr. Li served as Vice President of Business Development and Licensing at Merck, where he was responsible for business development activities of late-stage inbound and outbound opportunities globally. Prior to Merck, Dr. Li was Executive Licensing Director, External R&D at Amgen where he served in various roles in research, business development and licensing for more than 15 years. Dr. Li obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York.

John Haurum, *CEO,* **F-star Biotechnology Ltd.**

John Haurum joined F-star as the CEO in May 2012. Previously he was VP Research at ImClone Systems, New York (2010-2012) and before then he was the Chief Scientific Officer and cofounder of Symphogen A/S, Denmark (2000-2009). After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.

Joseph Sum, *Director of Research,* **EcoR1 Capital, LLC**

Joseph Sum has spent the past eight years hunting for promising investments that may lead to solutions for devastating diseases. As the Director of Research at EcoR1 Capital LLC, Mr. Sum identifies and assesses opportunities to fund talented management teams in pursuit of novel therapeutic drugs and technologies. He was previously a biotech specialist at a $15B asset management firm, and worked as an Analyst for BVF Partners, where he led the successful spin off of Ziarco Pharma from Pfizer. Mr. Sum serves on the board of the New York-based Breast Cancer Task Force, which provides early cancer detection and treatment services to patients without health insurance, and has served on the boards of Ziarco Pharma and Airmid, Inc. He has Bachelor of Science degrees in Chemical Engineering and Materials Engineering from the University of California, Berkeley, and is a CFA Charterholder.

Speakers

Jürgen Gamer, *VP Business Development,* **APOGENIX AG**

Jürgen Gamer joined Apogenix AG as VP, Business Development in January 2006. From 2000 to 2005 he worked for Graffinity AG/Santhera Pharmaceuticals AG as VP, Business Development and Project Management aquiring deals and leading alliance management. In the years from 1998 to 2000 Jürgen Gamer served at Clontech Lab. Inc., USA as Head of Business Development Europe where he was responsible for the licensing business in Europe. His industrial career started at BASF Pharma from 1995 to 1998 in the life science department. He obtained his Ph.D. in 1995 with „summa cum laude" from the "Zentrum für Molekulare Biologie" Heidelberg (ZMBH) at the University of Heidelberg.

Kuldeep Neote, *Senior Director, New Venture and Scout,* **J&J Innovation**

Kuldeep Neote, Ph.D., is Senior Director at J&J Innovation Center-Boston, and is responsible for New Venture and Scouting opportunities in the areas of Oncology and Immunology in the East Coast.

Dr. Neote is trained as a Molecule Biologist with an extensive background in drug discovery. He has been focused in the area of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Throughout his career, he has looked at creative scientific and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scientific discoveries working in conjunction with academic and biotech companies.

Formerly, Dr. Neote was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN. Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that lead to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech.

Dr. Neote earned her BSc. in Microbial and Cellular Biology at the University of Calgary, Calgary, Canada, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, Toronto, Canada, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.

Lee Greenberger, *SVP, CSO,* **The Leukemia Lymphoma Society**

Lee Greenberger, PhD. is Chief Scientific Officer of the Leukemia & Lymphoma Society. He is responsible for planning and executing the strategy for all LLS research programs, including grant funding programs, the Therapy Acceleration Program (TAP), as well as other research initiatives. Dr. Greenberger guides LLS's efforts to translate innovative research into clinical trials that ultimately will pave the way for new therapies to treat blood cancers.

Most recently, Greenberger was the global head of search and diligence for oncology and immunology at Bristol-Myers Squibb where he examined opportunities for over 200 oncology companies and helped set the business strategy for oncology and immunology. Prior to that, he served for six years as vice president for research at Enzon Pharmaceuticals where he was responsible for pre-clinical pharmacology, toxicology, process development, and analytical chemistry efforts associated with the discovery and development of oncology assets. Greenberger also held positions of increasing responsibility in the research organizations of Johnson & Johnson and Wyeth Pharmaceuticals, where he began his industry career in 1990 at American Cyanamid/Lederle Laboratories, which was later acquired by Wyeth. He was given the President's Award for his work at Wyeth.

Dr. Greenberger holds a bachelor's degree from the University of Rochester and a Ph.D. from Emory University. He has done post-doctoral work at Columbia University and was on faculty at the Albert Einstein College of Medicine. Greenberger has published more than 85 publications, mostly focused on oncology, during his research career.

Speakers

Louise Perkins, *Chief Scientific Officer,* **Melanoma Research Alliance**

Dr. Perkins joined the Melanoma Research Alliance as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA's scientific strategy including its research award program and annual Scientific Retreat. Her interests center on translational research including genomics, drug discovery and advancement of novel therapeutic approaches. Prior to joining the MRA, she was Chief Scientific Officer at the Multiple Myeloma Research Foundation (MMRF) for five years, following a 16-year research career at two major pharmaceutical companies. While at the MMRF, Dr. Perkins led the expansion of its venture philanthropy activities including its Biotech Investment Award program and development of the scientific direction of its CoMMpass longitudinal study. Prior to joining the MMRF, Dr. Perkins was Director of Cancer Research at Bayer Pharmaceuticals, where she contributed to advancing novel targeted therapies toward clinical study including Nexavar® and other innovative signal transduction inhibitors. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute participating in early-stage programs, including novel target-finding using human genomics data. Dr. Perkins graduated from the University of Michigan with a PhD and MS in Biological Chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her BS in Zoology from the University of North Carolina at Chapel Hill. Dr. Perkins became a member of the Board of Directors of the Foundation for Sarcoidosis Research in late 2015.

Madhusudan Peshwa, *CSO and Executive Vice President of Cellular Therapies,* **MaxCyte, Inc.**

Dr. Peshwa currently serves as Chief Scientific Officer at MaxCyte, having joined the Company in 2005. He was Executive Vice President for Research and Development at NewNeural, a start-up stem cell therapy company. Previously, Dr. Peshwa served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where he was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and in cGMP systems for the development of engineered cell and tissue products and for biopharmaceuticals production. Dr. Peshwa obtained his PhD in chemical engineering from the University of Minnesota and his BTech in chemical engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.

Mani Mohindru, *Chief Strategy Officer,* **Curis, Inc.**

Dr. Mani Mohindru joined Curis, Inc. in June 2013 as Vice President of Corporate Strategy and Investor Relations, and has held subsequent positions as Senior VP of Corporate Strategy and Investor Relations and, most recently, Chief Strategy Officer. Previously, she spent several years as a Wall Street equity research analyst covering the biotechnology sector, including analyst roles at ThinkEquity LLC, Credit Suisse and UBS. She was also a co-founder of a privately-held biotechnology company. Dr. Mohindru was previously a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health), and also a managing director in healthcare investment banking at Capstone Investments. She received her Ph.D. in Neurosciences from Northwestern University and has a B.Sc. in Human Biology and a M.S. in Biotechnology from the All India Institute of Medical Sciences, New Delhi, India.

Mark Frohlich, *EVP, Portfolio Strategy,* **Juno Therapeutics, Inc.**

Mark W. Frohlich, M.D., is Executive Vice President, Portfolio Strategy, at Juno Therapeutics, which he joined in February 2014. Prior to Juno, Dr. Frohlich served as Executive Vice President of Research and Development and Chief Medical Officer at Dendreon Corporation, where he led teams responsible for the U.S. and European approval of Provenge, the first FDA-licensed active cellular immunotherapy for cancer. Prior to joining Dendreon, he served as Vice President of Xcyte Therapies, where he pursued the development of an autologous T-cell therapy for cancer. Dr. Frohlich is a board-certified medical oncologist. He received his M.D. from Harvard Medical School and did his post-doctoral training in Internal Medicine and Oncology at the University of California, San Francisco. He subsequently served on the faculty there, where he was active in translational and clinical research. He has a B.S. from Yale College in Electrical Engineering and Economics.

Speakers

Mark Schwartz, *President & CEO,* **Galena Biopharma, Inc.**

Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry and was appointed President and Chief Executive Officer in 2014. Previously, he was Galena's Executive Vice President and Chief Operating Officer following Galena's 2011 acquisition of Apthera, Inc. where he served as the company's President and CEO. Prior to Apthera, Dr. Schwartz served for five years as President and CEO of Bayhill Therapeutics, a company developing an innovative DNA vaccine platform for the treatment of autoimmune diseases where he completed a successful partnership with Genentech for the development of the company's Type 1 diabetes vaccine. He had also served as President and CEO of Calyx Therapeutics, which expanded significantly, and completed key Phase 1 and Phase 2 international clinical trials of novel anti-inflammatory compounds during his tenure. Earlier in his career, Dr. Schwartz held a range of positions in R&D, marketing, sales, business development and executive management at Trega BioSciences, Incyte Genomics, Synteni, Tripos Inc., Applied Biosystems and DuPont Diagnostics.

Mike Rice, *Senior Consultant,* **Defined Health**

Mike joined Defined Health in 2005, bringing over 10 years of experience as a biotech entrepreneur. At Defined Health, Mike leads projects related to evaluating technology platforms and therapeutic opportunities for Rare Disorders and Genetic Disease and Endocrinology. He also co-heads the oncology and Cardiovascular & Metabolics practices. Prior to Defined Health, Mike was involved in entrepreneurial activities advancing non-viral gene therapy and gene editing approaches to human therapeutics and agricultural trait improvement. Mike was a technological founder and held positions in Business Development and New Product Planning at Tapestry Pharmaceuticals, Inc. and Kimeragen, Inc. and was Project Leader in Genomics at the Delaware Biotechnology Institute.

Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual property and publication portfolio pertaining to cancer genetics, DNA repair, human gene therapy, molecular diagnostics, and agricultural trait improvement. His past positions involved exposure to Venture Capital and financing, translational medicine and business development and licensing.

Mike holds an MBA, with a concentration in New Venture Creation, Biotechnology from the Alfred Lerner School of Business and Economics, at the University of Delaware, an MS in Molecular Pharmacology from Thomas Jefferson University and a Bachelor of Science degree in Biology from the University of Delaware.

Mohamed Ragab, *VP Oncology, S&E, BD,* **Bristol-Myers Squibb**

Mohamed H. Ragab, MD is the Global Head, Search and Evaluation, Immuno-Oncology/ Oncology in the Business Development group at BMS. His day to day responsibilities include conducting initial evaluation and detailed assessment of licensing and acquisition opportunities in the oncology/immune-oncology therapeutic area.

Mohamed joined Search and Evaluation at BMS in 2013 from his previous position as Global Partnering Head, Oncology, at Hoffman La Roche, Inc. Prior to joining BMS, Mohamed held positions within Oncology/Business Development at Pfizer, Ortho Biotech, Schering Plough and Egyptian National Cancer Institute. Additionally, Mohamed represents BMS on the board of Bio NJ.

Mohamed has a Bachelor of Medicine and Surgery degree and a M.Sc. in Radiation Oncology from Cairo University School of Medicine.

Speakers

Niels Emmerich, *Senior Director, Global Head Search & Evaluation Oncology,* **AbbVie, Inc.**

Niels joined the pharmaceutical division of Abbott (now AbbVie) in 2011 and currently serves as Senior Director, Global Head of Search & Evaluation, Oncology. Prior to joining AbbVie, Niels was CEO of BioPheresis, an immuno-oncology-focused medical device company. Before joining BioPheresis Niels was co-founder and COO immatics biotechnologies, a biotech company focused on identification of T-cell antigens. Prior to that Niels was an associate with McKinsey & Company. Niels received a Ph.D in Immunology and M.Sc. in Biology from University of Tuebingen.

Padmanee Sharma, *Professor, Department of Genitourinary Medical Oncology & Department of Immunology,* **University of Texas MD Anderson Cancer Center**

Dr. Sharma is a trained medical oncologist and immunologist whose research work is focused on investigating mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. She's the Principal Investigator of multiple immunotherapy clinical trials and conducts translational laboratory studies related to these trials. Her studies enable development of novel immunotherapy strategies for the treatment of cancer patients. She's Professor, Departments of Genitourinary Medical Oncology and Immunology, and Scientific Director, Immunotherapy Platform, at M. D. Anderson Cancer Center. She also just recently accepted the position as Co-Director of Parker Institute for Cancer Immunotherapy at M.D. Anderson Cancer Center. She has independent funding consisting of a DOD Idea Development Award (2010), a CPRIT Individual Investigator Award (2011), a NIH/NCI R01 grant (2012), and an AACR-CRI-SU2C Immunology grant (2013).

Paul Lammers, *President & CEO,* **Mirna Therapeutics, Inc.**

Paul Lammers, M.D., M.Sc., joined Mirna Therapeutics in November 2009 as its President, CEO, and Director of the Board, during which time period was able to secure approximately $150 million in both private and public financings for the Company. Prior to joining Mirna Therapeutics, Dr. Lammers served as President of Repros Therapeutics in The Woodlands, Texas, after having served for 6 years as the Chief Medical Officer for EMD Serono Inc., a Division of German pharmaceutical company, Merck KgA. He began his career with Dutch pharmaceutical company, Organon, spending 8 years in the commercial and clinical operations in Europe and the US. He also served 4 years as Senior Vice President of clinical and regulatory affairs at Zonagen in The Woodlands, TX. Dr. Lammers obtained his Medical and Masters of Science degrees from Radboud University in Nijmegen, The Netherlands, and moved with his family to the US in 1992.

Paul Rennert, *President & CSO,* **Aleta Biotherapeutics, Inc.**

Paul is a Biotechnology Executive with extensive strategic and leadership experience. He focuses on the alignment of R&D, commercial and clinical strategies to drive effective, efficient and successful drug development. His industry expertise covers bench to IND and clinical trial development of biological and small molecule drugs for oncology, autoimmunity, chronic inflammation and fibrosis. Over the past four years he has partnered with investors, biopharma and academic centers to develop diverse biotechnology companies. Paul's most recent venture is Aleta Biotherapeutics Inc, a cell therapeutics company developing unique technology of broad utility in the CAR T, TCR and TIL fields.

His ability to work so broadly across our industry is based on a long and successful career within biotech, highlighted by multiple successful drug-development campaigns, over 30 patents filed and granted, and more than 80 peer-reviewed publications including recent publications in Nature Reviews Drug Discovery, Immunity, PNAS USA, JCI, and the Journal of Virology. Paul's most recent publication is the book entitled "*Novel Immunotherapeutic Approaches to the Treatment of Cancer*", for which he served as editor.

Paul's Current Positions

Co-Founder, President & CSO, Aleta Biotherapeutics Inc. Aleta is developing transformative technologies for use in cellular therapeutics for the treatment of cancer.

Founder & Principal, SugarCone Biotech Consultants LLC. SugarCone Biotech provides C-Suite strategic consulting for the biotech, investment, and pharmaceutical industries.

Co-Founder & Chief Scientific Officer, Videre Biotherapeutics. Videre Biotherapeutics is a targeted-drug-conjugate company with a singular focus on pathways critical for tumor cell survival in protected "niches".

Speakers

Peter Emtage, *Senior Vice President, Research,* **Cell Design Labs**

Peter Emtage, Ph.D. is the SVP of Research at Cell Design Labs (CDL). Prior to joining CDL, Peter held senior positions at Intrexon, Medimmune and Femta Pharmaceuticals. Peter is an immunologist by training and over the past 20 years has focused on developing drugs to modulate the immune response in humans. His work in oncology, autoimmunity and infectious disease has included the utilization of viral and non-viral delivery systems, chimeric antigen receptor and TCR adoptive T cell modalities, and monoclonal antibody development. His career started with a post-doctoral fellowship at the National Institutes of Health followed by his role as Research Scientist at Aventis Pasteur and then Instructor in Medicine at Harvard Medical School.

Peter Sandor, *Vice President, Head of Oncology Therapeutic Area Marketing Strategy,* **Astellas Pharma US, Inc.**

In this role, Peter provides commercial leadership for project's within the oncology therapeutic area and plays an integral role in the expansion of Astellas's presence in oncology

Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen's oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

Rena Conti, *Assistant Professor Hematology/Oncology,* **The University of Chicago Department of Pediatrics**

Rena Conti is associate professor at the University of Chicago departments of pediatrics and public health sciences. She is an expert in health policy pursuing research in pharmacoeconomics. She has specific expertise in estimating the benefits and costs of new medical technology in the U.S. using big data, including drugs and devices to treat cancer and mental health. Projects she has recently completed include examining the prevalence and associated costs of "off label" cancer drugs use, the supply and pricing of generic specialty drugs and the determinants of branded drug launch prices.

Robert Petit, *Executive Vice President and Chief Scientific Officer,* **Advaxis, Inc.**

Dr. Robert Petit is the Chief Scientific Officer at Advaxis, Inc. and is responsible for shaping future products and combinations and has personally championed the adaptation of the Advaxis platform toward multiple tumor driver targets as well as personalized neoepitopes. Professionally, he has over 25 years of experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational medicine, and clinical development. Robert has designed and conducted U.S. and international clinical evaluation programs for numerous therapies from Translation through clinical Phase 1-4. Dr. Petit joined Advaxis from Bristol-Myers Squibb where he was U.S. Medical Strategy Lead for the ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol-Myers Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr. Petit has significant regulatory filing experience and has contributed to five NDA/BLA filings. Prior to joining industry, Robert co-founded an immune-oncology program affiliated with St. Luke's and the Medical College of Wisconsin with an appointment in pathology and laboratory medicine. He holds a doctorate from the Ohio State University College of Medicine and a Bachelor of Science from Indiana University.

Speakers

Shaun McNulty, *Chief Scientific Officer,* **Biosceptre International Ltd.**

Shaun joined Biosceptre in January 2014. With over 20 years of experience working in the Pharmaceutical and Biotechnology sectors across a range of functions from target identification, drug discovery and portfolio management to product and commercial development. Shaun is experienced in strategic planning, drug discovery and product development and brings broad industry understanding to the scientific and commercial sides of the business.

Having obtained his doctorate from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge. He then held positions at GSK, Pfizer and Syntaxin, managing a number of scientific teams, international drug discovery projects and drug development portfolios. Shaun joined ImmBio in 2008, establishing scientific links and the commercial strategy that led to the company obtaining multiple grants to develop its vaccine products. Currently, Shaun directs Biosceptre International's portfolio of drugs through research and clinical development stages.

Sophie Kornowski-Bonnet, *Head of Roche Partnering,* **F.Hoffmann-La Roche AG**

Sophie Kornowski-Bonnet, PhD, is Global Head of Roche Partnering and a member of the Roche Corporate Executive Committee, based at Roche's headquarters in Basel, Switzerland.

Her career has taken her from Paris to New York, via Chicago. She began at Abbott Diagnostics in France, first in regulatory affairs, then moved to Abbott Pharmaceuticals in Chicago and was in Market Research, then Medical Representative in NYC. For four years in the USA and then two years in France, she held positions in Strategic Marketing and as Business Unit Head, Neuroscience for Sanofi Winthrop.

She further pursued her professional career within the Merck-Sharp & Dohme Group as Head of Strategic Planning, France, before relocating to Israel as General Manager to create and develop the affiliate for the group, subsequently holding respectively the functions of Vice-President of Rheumatology and Analgesia in the US, then Rheumatology and Cardiology head for France.

She joined Roche France in March 2007 as General Manager, and was then appointed Head of Roche Partnering in February 2012. She holds a PhD in pharmacy from the Faculty of Pharmacy in Paris, France, and an MBA in Marketing and Finance from the University of Chicago. She also has the distinction of having been inducted into the French Legion of Honor (*Ordre national de la Légion d'honneur*) by the French Minister of Research in recognition of her achievements. In 2014, *FierceBiotech* named Sophie one of the Top Women in Biotech. In her personal time, Sophie enjoys jogging, art, being with family and friends - and more than anything else, spending time with her teenage son.

Thilo Schroeder, *Partner,* **Nextech Invest Ltd.**

Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors. He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

Advaxis, Inc.

www.advaxis.com

CONTACT
Robert Petit
Executive Vice President and Chief Scientific Officer

ADDRESS
305 College Rd East
Princeton, NJ 08540
USA

TELEPHONE
+1 609 452 9813

EMAIL
ir@advaxis.com

YEAR FOUNDED
2002

SECTOR

- Biotechnology

COMPANY PROFILE

Advaxis is a clinical-stage biotechnology company focused on developing cancer immunotherapies that use the body's natural immune system to redirect the immune response to kill cancer. For decades, cancer researchers have been trying to stimulate the body's immune system to identify and kill cancer cells, with the goal of creating a standard "immunologic" treatment against tumors that is more effective and more tolerable than traditional chemotherapy or radiation. Our clinical programs are evaluating the ability of Advaxis cancer immunotherapies to improve survival and reduce the frequency and severity of side-effects commonly associated with standard chemotherapy and radiation.

MANAGEMENT

Daniel J. O'Connor, *President and Chief Executive Officer*
Greg Mayes, *EVP and Chief Operating Officer*
Sara Bonstein, *SVP and Chief Financial Officer*
Robert Petit, *EVP and Chief Scientific Officer*
Thomas Hare, *Vice President, Clinical Operations*
Robert Ashworth, *Vice President, Regulatory Affairs*
Mayo Pujols, *Vice President, Manufacturing*

Continued...

Aethlon Medical, Inc.

www.aethlonmedical.com

CONTACT
James A. Joyce
Chairman and
Chief Executive Officer

ADDRESS
9635 Granite Ridge Drive,
Suite 100
San Diego, CA 92123
USA

TELEPHONE
+1 858 459 7800

EMAIL
jj@aethlonmedical.com

YEAR FOUNDED
1999

SECTORS

• Biotechnology • Medical Devices

COMPANY PROFILE

The Aethlon Medical mission is to create innovative medical devices and diagnostics that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.

Our Aethlon ADAPT™ System provides the basis for a new class of therapeutics that target the selective removal of disease-enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.

Our subsidiary, Exosome Sciences, has proof of concept data for Lectin Affinity Diagnostics which may enable:

1. Early stage cancer screening tests based on the high-sensitivity capture of tumor-secreted exosomes in blood or urine.
2. Companion diagnostics based on the analysis of microRNA, proteins and/or other molecules contained in tumor-secreted exosomes captured from a blood or urine sample.

INVESTMENT & LICENSING OPPORTUNITIES

Rapid Removal of Tumor Secreted Exosomes from Circulation

An understanding is emerging that tumor-secreted exosomes are involved in tumor growth and metastasis and that therefore, abrupt removal of exosomes from the blood stream could immediately impact progression-free survival and overall survival in a variety of cancers.

Aethlon Medical's Hemopurifier device is a plasmapheresis-like filter cartridge with a proprietary lectin inserted into the extra-luminal space of the cartridge as an affinity agent to capture disease-causing pathogens while the remaining blood and plasma particles return to the patient's circulation. A Safety Study is currently underway under an approved IDE for investigation in ESRD patients infected with Hepatitis C. The device has been found to capture exosomes from the circulation. A treatment regimen for cancer patients might be similar to that of ESRD patients on dialysis.

This device may also be useful in collection of a large number of a patient's exosomes for use in an autologous modified-exosome therapy process for the targeted delivery of chemo- or other therapeutics, if developed.

Clinical validation comes from 100 treatment experiences in Hepatitis C, HIV, and Ebola.

Exosome-Based Screening Diagnostics and Companion Diagnostics

Validation is emerging that tumor-secreted exosomes may be a robust and dynamic source of biomarkers for early cancer screening tests and companion diagnostics. Exosomes mirror the features of the parent cell and are altered upon infection, transformation or injury. Detection of exosomal components associated with specific pathologies can be utilized as clinically relevant markers. Analyzing multiple exosomal components allows multiplexing to optimize specificity and sensitivity. Exosomes are very stable and make a liquid biopsy possible.

Aethlon Medical and its subsidiary Exosome Sciences discovered that tumor-secreted exosomes bind to lectins and therefore lectins can be an important component in the development of cancer screening tests and companion diagnostics in oncology.

ESI's diagnostic platform, the Enzyme Linked Lectin Specific Assay (ELLSA), in which lectin affinity has replaced the capture antibody of ELISA, has been shown to detect and quantify the presence of exosomes underlying HIV, TB, and ovarian, bladder, colorectal, lung and pancreatic cancer.

Continued...

Aethlon Medical, Inc.

www.aethlonmedical.com

CONTACT
James A. Joyce
Chairman and
Chief Executive Officer

ADDRESS
9635 Granite Ridge Drive,
Suite 100
San Diego, CA 92123
USA

TELEPHONE
+1 858 459 7800

EMAIL
jj@aethlonmedical.com

YEAR FOUNDED
1999

...continued

MANAGEMENT

James A. Joyce, *Chairman and Chief Executive Officer*
Mr. Joyce is the founder, Chairman and Chief Executive Officer of Aethlon Medical. Under his leadership, Aethlon has transformed the concept of a selective therapeutic filtration device (The Aethlon Hemopurifier®) into the reality of treating both HIV and hepatitis C patients in a clinical setting. Follow-on research has further validated the ability of the Hemopurifier® to capture a broad-spectrum of bioterror and pandemic threats as well as immunosuppressive cancer exosomes. Mr. Joyce has originated numerous collaborative relationships with government and non-government research organizations, has authored supporting publications and reports, and raised capital resources to support the mission of Aethlon Medical. He has represented the Company on CNN, NBC, ABC, and other media outlets and has testified before Congress on issues related to Project BioShield legislation and the deployment of the Aethlon Hemopurifier® as a countermeasure against biological weapons. His efforts on Capital Hill were instrumental in expanding the definition of treatment countermeasure in Project BioShield legislation to include medical devices. In May 2011, the Company introduced the Aethlon ADAPT™ system to advance Mr. Joyce's vision of an expansive device platform that converges affinity drug agents with plasma membrane technology to create new candidate therapies against life-threatening disease conditions. From February 1993 until founding Aethlon Medical, Mr. Joyce was Chief Executive Officer of James Joyce & Associates. Previously he was founder and Chief Executive Officer of Mission Labs, Inc., was a principal at London Zurich Securities, Inc., and was a member of the Denver Broncos Football Club of the National Football League. Mr. Joyce is a graduate of the University of Maryland.

Richard H. Tullis, Ph.D., *Senior Vice President, Chief Science Officer*
Dr. Tullis has extensive biotechnology management and research experience, and is the founder of Syngen Research, a wholly-owned subsidiary of Aethlon Medical, Inc. Dr. Tullis became a Vice President and Director of Aethlon Medical, Inc. in January of 2000, and succeeded Dr. Clara M. Ambrus as Chief Scientific Officer in June of 2001. Previously, Dr. Tullis co-founded Molecular Biosystems, Inc., a former NYSE company. At Molecular Biosystems, Dr. Tullis was Director of Research and Development, Director of Oligonucleotide Hybridization, Senior Research Scientist and Member of the Board of Directors. In research, Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxy-phosphorochloridites. Dr. Tullis also co-developed the first applications of covalently coupled DNA-enzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985, Dr. Tullis founded, and served as President and CEO of Synthetic Genetics, Inc., a pioneer in custom DNA synthesis, which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interim-CEO of Genetic Vectors, Inc., which completed its IPO under his management, and was co-founder of DNA Sciences, Inc., a company that was eventually acquired by Genetic Vectors. Dr Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive post-doctoral work at UCSD, USC, and The Scripps Research Institute.

APOGENIX AG

www.apogenix.com

CONTACT
Dr. Juergen Gamer
VP Business Development

ADDRESS
Im Neuenheimer Feld 584,
69120 Heidelberg
Germany

TELEPHONE
+49 0 6221 58608 0

EMAIL
contact@apogenix.com

YEAR FOUNDED
2006

SECTOR

- Biotechnology

COMPANY PROFILE

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.

PRODUCT PIPELINE



APG101

Apogenix' lead drug candidate APG101 is a CD95 ligand checkpoint inhibitor consisting of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody. APG101 is being developed for the treatment of solid tumors and malignant hematological diseases and has been evaluated in the treatment of glioblastoma and myelodysplastic syndromes (MDS). Clinical efficacy data has been demonstrated in a controlled PII study in glioblastoma and a PI/II study in MDS.

Glioblastoma: In a randomized, controlled phase II efficacy trial in recurrent glioblastoma, treatment with APG101 in combination with radiotherapy has shown clinical superiority in all study endpoints compared to treatment with radiotherapy alone. Both progression-free survival at six months, the primary endpoint of the trial, and median progression-free survival were met with statistical significance. A new biomarker was identified associated with the CD95 ligand – the target of APG101. The trial showed a significant increase in median overall survival in biomarker-positive patients treated with APG101.

MDS: Results of the phase I trial with APG101 in low and intermediate-1 risk MDS patients – who represent 70 percent of all MDS patients – reveal an increase in erythrocyte precursor cells and a trend toward reduction in transfusion frequency after treatment with APG101.

The excellent tolerability of APG101 was shown in a double-blind, placebo-controlled phase I trial in healthy volunteers. Even the highest dose of 20 mg/kg body weight was very well tolerated and no anti-drug antibodies against APG101 were detected.

Continued...

APOGENIX AG

www.apogenix.com

CONTACT
Dr. Juergen Gamer
VP Business Development

ADDRESS
Im Neuenheimer Feld 584,
69120 Heidelberg
Germany

TELEPHONE
+49 0 6221 58608 0

EMAIL
contact@apogenix.com

YEAR FOUNDED
2006

...continued

HERA Technology Platform

Apogenix has developed a proprietary technology platform for the construction of novel hexavalent TNF superfamily receptor agonists (HERA). This single-chain TNFSF (tumor necrosis factor superfamily) technology is superior to other biologics targeting TNFSF pathways, such as agonistic antibodies. HERA proteins have been developed for the TNF receptors TRAIL-R, OX40, CD40, CD70, GITR, 4-1BB. The Apogenix protein engineering concept allows for the creation of a plethora of anti-cancer biologics, including trivalent and hexavalent protein formats with differing pharmacodynamic and pharmacokinetic properties.

Whereas antibodies can only bind two TNFSF receptors in a spatially undefined manner and require secondary cross-linking via Fcγreceptors. the Apogenix' hexavalent compounds lead to well-defined TNFSF receptor clustering without the need for further cross-linking. This results in a sufficient level of the appropriate signal being transmitted into the target cell, whereas agonistic antibodies transmit these signals at insufficient levels.

INVESTMENT & LICENSING OPPORTUNITIES

APG101

Apogenix is looking for partners allowing the further development of APG101 in cancer.

HERA Candidates

Apogenix is looking for partners allowing the further development of the HERA proteins in cancer.

The approach has been validated by a licensing deal with ABBVIE exclusively for one of its HERA proteins.

MANAGEMENT

Dr. Thomas Hoeger, *CEO*
Dr. Harald Fricke, *CMO*
Dr. Peter Willinger, *CFO*

BerGenBio AS

www.bergenbio.com

CONTACT
Mr. Richard Godfrey
Chief Executive Officer

ADDRESS
BerGenBio AS
Jonas Lies vei 91
5009, Bergen
Norway

TELEPHONE
+47 535 01 564

EMAIL
post@bergenbio.com

YEAR FOUNDED
2007

SECTOR

- Biotechnology

COMPANY PROFILE

BerGenBio is a clinical stage biopharmaceutical company focused on developing first-in-class EMT inhibitors.

The Company is a world leader in understanding the biology of epithelial-mesenchymal transition (EMT), which is widely recognised as a key pathway in immune evasion, acquired cancer drug-resistance and metastasis. Building on this original biological insight BerGenBio is developing a promising pipeline of first-in-class AXL and other EMT inhibitors.

PRODUCT PIPELINE

BGB324
Highly selective, orally bioavailable AXL tyrosine kinas inhibitor
Phase I/II AML
Phase I/II NSCLC
Phase II NSCLC + CPI
Phase II Breast + CPI
Phase II Melanoma + CPI
Biomarkers and CDx

BGB101 - AXL mAb
Humanised, Preclincial, scale up stage.

BGB002 - small molecule, proprietary taget
Pre-clinical.

INVESTMENT & LICENSING OPPORTUNITIES

BGB324 & **BGB101**

MANAGEMENT

Mr. Richard Godfrey, *Chief Executive Officer*
Prof. James Lorens, *Chief Scientific Officer*
Dr. Murray Yule, *Clinical Development Officer*
Mr. Petter Nielsen, *Chief Financial Officer*
Dr. Anthony Brown, *Research Director*
Dr. Endre Kjærland, *Associate Director of IP and Contracts*
Dr. Julia Schölermann, *Business Support Manager*

Biosceptre International Ltd.

www.biosceptre.com

CONTACT
Shaun McNulty
Chief Scientific Officer

ADDRESS
Jonas Webb Building
Babraham Research Campus
Babraham,
Cambridge CB22 3AT
United Kingdom

TELEPHONE
+44 1223 496 090

EMAIL
info@biosceptre.com

YEAR FOUNDED
2002

SECTORS

• Biotechnology • Diagnostics • Pharmaceuticals/Licensing

FINANCIAL SUMMARY

Biosceptre is a privately funded business. Biosceptre is currently undertaking a private round fund raise currently underway fo £25m with Peel Hunt (UK), anticipated to list in 2017.

COMPANY PROFILE

Biosceptre is a UK based biotech R&D business investigating and exploiting a promising new target for the treatment of cancer – nfP2X7. nfP2X7 is a highly specific cancer target. Its very low cross reactivity with normal tissues along with the breadth of its presence in cancer, promises disruptive potential in the field of immunotherapy oncology

Biosceptre has multiple programs in pipeline that exploit this new nfP2X7 oncology target via a range of therapeutic modalities. Each has the potential to be a blockbuster in the treatment of cancer either individually or in combination with other treatments

Biosceptres' IP portfolio and expertise around the unique biology of the nfP2X7 target also promises significant potential for application & licensing across advanced therapeutic technologies, diagnostic and veterinarian uses.

PRODUCT PIPELINE



BIL03 - Phase I

BIL03s is a human domain antibody developed via phage display which binds specifically to nfP2X7 (a conformationally distinct variant of the P2X7 receptor that occurs on many cancer cell types) but not to P2X7 which is present on cells in a range of healthy tissues.

BIL03s is intended to treat a range of solid tumours by infusion.

The nfP2X7 form of P2X7 is associated with proliferation and survival signaling pathways which have a role in cancer cell survival and proliferation. Binding of BIL03s drives internalization of the nfP2X7 receptor, reducing aberrant signalling.

BIL03s has shown an excellent safety profile in man via compassionate access programs, and will enter the clinic in a Phase I trial in 2016.

BIL06v - Phase I

BIL06v is a peptide-protein conjugate vaccine intended as a therapeutic against a range of solid tumours. BIL03s elicits a titre of endogenous antibodies specifically against the nfP2X7 receptor which is a conformationally

Continued...

Biosceptre International Ltd.

www.biosceptre.com

CONTACT
Shaun McNulty
Chief Scientific Officer

ADDRESS
Jonas Webb Building
Babraham Research Campus
Babraham,
Cambridge CB22 3AT
United Kingdom

TELEPHONE
+44 1223 496 090

EMAIL
info@biosceptre.com

YEAR FOUNDED
2002

...continued

distinct variant of the P2X7 receptor that occurs on many cancer cell types. This antibody response does not bind to the P2X7 receptor which is present on cells in a range of healthy tissues.

The nfP2X7 form of P2X7 is associated with proliferation and survival signaling pathways which have a role in cancer cell survival and proliferation.

BIL06v is intended to be used as a therapeutic treatment for a range of solid tumours by vaccination.

BIL010t - Phase 2

BIL010t is a polyclonal topical product intended as a therapeutic against skin cancers including Basal Cell Carcinoma. BIL010t binds to the nfP2X7 receptor which is a conformationally distinct variant of the P2X7 receptor that occurs on many cancer cell types. BIL010t does not bind to the P2X7 receptor which is present on cells in a range of healthy tissues.

BIL010t has successfully completed a Phase 1 trial which delivered an excellent safety profile, as well as showing signs of efficacy in man.

BIL010t will enter a Phase II trial in late 2016.

MANAGEMENT

Mr. Gavin Currie, *Chief Executive Officer*
Dr. Shaun McNulty, *Chief Scientific Officer*
Mr. Daniel Barton, *Director of Investor Relations*

Biothera Pharmaceuticals, Inc.

www.biothera.com

CONTACT
Barry Labinger
Chief Executive Officer

ADDRESS
3388 Mike Collins Drive,
Eagan, MN 55121
USA

TELEPHONE
+1 651-675-0300

EMAIL
bgacki@biothera.com

YEAR FOUNDED
1997

SECTOR

- Biotechnology

COMPANY PROFILE

Biothera Pharmaceuticals, Inc. is advancing Imprime PGG, a first-in-class, clinical-stage oncology immunotherapeutic that acts as an "ignition switch" to drive a robust, coordinated anti-cancer immune response. While cancers can actively avoid detection by the immune system, Imprime PGG can overcome this by re-awakening the body's innate defenses. Biothera has established extensive proof of concept and safety results for its lead asset in combination with anti-cancer antibodies and is pursuing additional clinical and translational research in 2016 prior to planned initiation of registration Phase 2/3 studies of Imprime PGG in 2017 – 18. Biothera has partnered with Merck, Eli Lilly and Company, and Cancer Research UK and has entered research collaborations with The Johns Hopkins University, Harvard University, Dartmouth, and the Wistar Institute. In addition, Biothera has assembled an intellectual property portfolio for Imprime PGG consisting of more than 100 US & international patents and patents pending.

PRODUCT PIPELINE

Imprime PGG / Phase 1b/2
Imprime PGG is a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in trials in over 400 subjects and has established proof of concept in multiple clinical studies, including single-arm and randomized phase 2 studies in non-small cell lung cancer, colorectal cancer, and chronic lymphocytic leukemia.

MANAGEMENT

Barry Labinger, *Chief Executive Officer*
José Iglesias, MD, *Chief Medical Officer*
Jeremy Graff, PhD, *Chief Scientific Officer*
Bill Gacki, *Chief Financial Officer (Interim)*
Carey Anderson, MSc, *Vice President, Quality and Regulatory Affairs*

Charité – Universitätsmedizin Berlin

www.charite.de/en

CONTACT
Frank S. Zollmann
Investigator

ADDRESS
Charitéplatz 1
10117 Berlin
Germany

TELEPHONE
+49 30 450 50

SECTOR

- Academia

COMPANY PROFILE

Charité is one of the largest university hospitals in Europe. All of our clinical care, research and teaching is delivered by physicians and researchers of the highest international standard. Charité proudly lays claim to more than half of all German Nobel Prize winners in Physiology or Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich. Charité is internationally renowned for its excellence in teaching and training. Charité – Universitätsmedizin Berlin represents a single medical faculty, which serves both Humboldt Universtität zu Berlin and Freie Universität Berlin. Charité extends over four campuses, and has close to 100 different Departments and Institutes, which make up a total of 17 different CharitéCenters. Having marked its 300-year anniversary in 2010, Charité is now one of the largest employers in Berlin, employing 13,200 staff (or 16,850 if including its subsidiaries), and with a total annual turnover of €1.6 billion.

PRODUCT PIPELINE

ATP6AP2 (RER) / preclinical development candidate (PDC)

ATP6AP2 (RER) is a promising novel oncological drug target. As unique pathophysiological nodal point, ATP6AP2 (RER) mediates pro-proliferative effects as well as cancer progression in vivo, highlighting its role as a primary target in various oncological indications as well as in second line therapy in patients with therapy-resistant cancer.

Our team develops – in cooperation with the contract research organizations Evotec AG and Experimental Pharmacology & Oncology (EPO) GmbH - first-in-class small molecules for multiple oncologic indications (e.g. sarcoma, pancreatic cancer, hepatocellular carcinoma, colorectal cancer), which are currently in the PDC stage.

MANAGEMENT

Frank S. Zollmann, *Investigator*

Curis, Inc.

www.curis.com

CONTACTS

Dr. Mani Mohindru
Chief Strategy Officer

Dr. Minji Kim
VP, Corporate and Business Development

ADDRESS
4 Maguire Road
Lexington, MA 02421
USA

TELEPHONE
+1 617 503 6500

EMAIL
info@curis.com

YEAR FOUNDED
2001

SECTOR

- Biotechnology

COMPANY PROFILE

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancers, including its lead development candidate, CUDC-907, that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/VISTA, including PD-L1/VISTA antagonist CA-170, as well as to oral small molecules designed to inhibit the IRAK4 kinase, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.

PRODUCT PIPELINE



*Subject to Curis' expectations to exercise option to exclusively license the Development Candidate(s) from this program

CUDC-90 (Dual HDAC & PI3K Inhibitor)7/Phase II

CUDC-907 is an orally-available, small molecule drug candidate in Phase 2 clinical testing for treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) that harbor alteration of the MYC oncogene. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CUDC-907 for the treatment of patients with DLBCL. CUDC-907 is also being developed in a Phase 1 clinical trial for treatment of patients with solid tumors.

Continued...

Curis, Inc.

www.curis.com

CONTACTS
Dr. Mani Mohindru
Chief Strategy Officer

Dr. Minji Kim
VP, Corporate and Business Development

ADDRESS
4 Maguire Road
Lexington, MA 02421
USA

TELEPHONE
+1 617 503 6500

EMAIL
info@curis.com

YEAR FOUNDED
2001

...continued

CA-170 (Oral Small Molecule PD- L1/VISTA Antagonist)
In October 2015, Curis licensed from Aurigene a first-in-class oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA, both of which function as negative checkpoint regulators of immune activation. CA-170 was selected from the broad PD-1 pathway antagonist program that the companies have been engaged in since the collaboration was established in January 2015. Preclinical data demonstrate that CA-170 can induce effective proliferation and IFN-y (Interferon-gamma) production (a cytokine that is produced by activated T cells and is a marker of T cell activation) by T cells that are specifically suppressed by PD-L1 or VISTA in culture. In addition, CA-170 also appears to have anti-tumor effects similar to anti-PD-1 or anti-VISTA antibodies in multiple in vivo tumor models and appears to have a good in vivo safety profile. Curis expects to initiate clinical studies with CA-170 in patients with advanced tumors in 2016.

CA-4948 (Oral, Small Molecule IRAK4 Kinase Inhibitor)/Preclinical
In October 2015, Curis exercised its option and licensed program of orally-available, small molecule inhibitors of IRAK4 kinase, including the development candidate, CA-4948 from Aurigene. The lead molecule is currently completing IND enbaling studies to support its clinical development in certain advanced hematologic cancers.

MANAGEMENT

Ali Fattaey, Ph.D., *President and Chief Executive Officer*
David Tuck, M.D., *Chief Medical Officer*
Mani Mohindru, Ph.D., *Chief Strategy Officer*
James Dentzer, *Chief Financial and Chief Administrative Officer*

Etubics Corporation

www.etubics.com

CONTACT
Frank Jones, Ph.D.
Chairman, Founder, Chief Executive Officer and Chief Scientific Officer

ADDRESS
410 W Harrison St, Seattle,
WA 98119,
USA

TELEPHONE
+1 206-838-5014

YEAR FOUNDED
2003

SECTOR

- Biotechnology

COMPANY PROFILE

Etubics Corporation is a clinical stage biotechnology company focused on developing immunotherapeutics for the treatment of cancer and vaccines against infectious diseases. The Company has a pipeline of product candidates based on our proprietary, advanced generation viral vector platform, the Etubics Platform, to generate both T cell mediated and antibody responses and its complimentary manufacturing human-based cell line. The Company's lead product, ETBX-011, has completed Phase 1/2 clinical trials in metastatic colorectal cancer patients. ETBX-011 targets carcinoembryonic antigen (CEA) which is expressed in many types of cancer and we believe the product has broad clinical application. Etubics Corporation has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, a part of the National Institutes of Health, to investigate a multi-targeted immunotherapy approach containing three tumor-associated antigens including ETBX-011. These three antigens are highly expressed in various human carcinomas and has the ability to simultaneously target all three which could be of significant clinical benefit in terms of overall survival of cancer patients. Additionally, the Company is manufacturing an immunotherapeutic that is directed against HER2/neu (ETBX-021). This product candidate may soon be employed in Phase 1 clinical trials for the treatment of patients with HER2+ breast cancer. Furthermore, the Company has a collaboration agreement with Duke University, Durham, NC for the development of a HER3 based breast cancer immunotherapeutic (ETBX-031) which is moving forward to clinical trials. Etubics Corporation also collaborates with Sanford Cancer Center, Sioux Falls, SD on the development of a product candidate that targets human papilloma virus (HPV) for the treatment of HPV induced cancers such as head and neck and cervical (ETBX-041). In addition, the Company is developing vaccines to combat infectious diseases and emerging pathogens, including a universal influenza vaccine (ETBX-051). Etubics Corporation was founded in 2003 and is headquartered in Seattle, Washington.

MANAGEMENT

Frank Jones, Ph.D., *Chairman, Founder, Chief Executive Officer and Chief Scientific Officer*

Ex Scientia Ltd.

www.exscientia.co.uk

CONTACTS

Mark Swindells
COO

Andrew Hopkins
CEO

ADDRESS

Lab 12 Dundee Incubator
James Lindsay Place
Dundee
DD1 5JJ
UK

TELEPHONE

+44 (0)1382 202136

EMAIL

contact@exscientia.co.uk

YEAR FOUNDED

2012

SECTOR

- Biotechnology

FINANCIAL SUMMARY

Collaborations with major pharma. See press releases for Sunovion and Sumitomo Dainippon Pharma.

Other financial information at Companies House UK.

COMPANY PROFILE

ex scientia is progressing a unique range of small molecule assets in the field of immuno-oncology. Our unparalleled design capability allows us to move beyond the restrictions of single target compounds to also design bispecific small molecules (a compound that can interact productively – at separate times – with two complementary targets. By applying our design approach we deliver compounds with clear market differentiation. Our lead portfolio is an adenosinergic focused strategy covering both single and bispecific opportunities.

MANAGEMENT

Andrew Hopkins, *CEO*
Mark Swindells, *COO*
Andy Bell, *Chief Chemist*

F-star Biotechnology Ltd.

www.f-star.com

CONTACT
John Haurum
CEO

ADDRESS
Eddeva B920
Babraham Research Campus
Cambridge,
CB22 3AT
UK

TELEPHONE
+44 (0)1223 497400

EMAIL
cambridge@f-star.com

YEAR FOUNDED
2006

SECTOR

- Biotechnology

COMPANY PROFILE

F-star designs and develops bispecific antibody products to improve the treatment of cancer. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products.

F-star's Modular Antibody Technology allows easy combination of antibody specificities in a "plug-and-play" manner to create unique mAb2 bispecific antibodies and exlpore their novel biology. An Fcab against a single target can be combined with the variable regions of as many different existing antibodies as desired. A mAb2 is full-length antibody which looks like mAb, works like mAb, behaves like mAb and performs beyond mAb.

F-star is developing several products in the immuno-oncology space and has partnerships with AbbVie, BMS, Merck Serono and Boehringer Ingelheim.

PRODUCT PIPELINE

FS102/phase I
FS102 is HER2-targeted Fcab, which works differently to current HER2-targeted therapies with the potential to overcome resistance to these drugs. In preclinical studies FS102 showed remarkable efficacy against HER2-positive cancers.

FS102 is currently being tested in phase I clinical trial against breast and gastric cancer through a partnership with Bristol-Myers Squibb.

FS118/preclinical development
First-in-class bispecific antibody dual checkpoint inhibitor for the treatment of cancer.

FS118 is designed using F-star's Modular Antibody Technology, which is ideally suited to produce the next generation of immuno-oncology therapeutics.

Multiple bispecific antibody product candidates in the space of immuno-oncology at discovery stage

INVESTMENT & LICENSING OPPORTUNITY

Out licensing Opportunity
Bispecific antibody assets in oncology and immuno-oncology

MANAGEMENT

John Haurum, *CEO*
Jane Dancer, *CBO*
Tolga Hassan, *CFO*
Neil Brewis, *CSO*

Galena Biopharma, Inc.

www.galenabiopharma.com

CONTACTS

Ms. Remy Bernarda
SVP, Investor Relations
& Corporate Communications

Dr. Mark W. Schwartz
President & Chief Executive Officer

ADDRESS
2000 Crow Canyon Place
Suite 380
San Ramon, CA 94583
USA

TELEPHONE
+1 925 498 7700

EMAIL
info@galenabiopharma.com

YEAR FOUNDED
1997

SECTOR

- Biotechnology

COMPANY PROFILE

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company's pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.

PRODUCT PIPELINE



NeuVax™ (nelipepimut-S) : Phase 3 and multiple Phase 2 trials

NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. It is the immunodominant peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to specific HLA molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut-S immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.

NeuVax is currently in an international, Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). PRESENT is targeting node positive HER2 IHC 1+/2+ patients (clinicaltrials.gov identifier: NCT01479244). Galena has two additional breast cancer studies ongoing with NeuVax in combination with trastuzumab (Herceptin®; Genentech/Roche): a Phase 2b trial in node positive and triple negative HER2 IHC 1+/2+ (clinicaltrials.gov identifier: NCT01570036); and, a Phase 2 trial in high risk, node positive or negative HER2 IHC 3+ patients (clinicaltrials.gov identifier: NCT02297698). Phase 2 clinical trials with NeuVax are also planned in patients with ductal carcinoma in situ (DCIS), and in patients with gastric cancer.

Continued...

Galena Biopharma, Inc.

www.galenabiopharma.com

CONTACTS

Ms. Remy Bernarda
SVP, Investor Relations
& Corporate Communications

Dr. Mark W. Schwartz
President & Chief Executive Officer

ADDRESS
2000 Crow Canyon Place
Suite 380
San Ramon, CA 94583
USA

TELEPHONE
+1 925 498 7700

EMAIL
info@galenabiopharma.com

YEAR FOUNDED
1997

...continued

GALE-301 & GALE-302 : Phase 2a

GALE-301 and GALE-302 are cancer immunotherapies that consist of a peptide derived from Folate Binding Protein (FBP) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in the adjuvant setting. GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as E39'. FBP is a well-validated therapeutic target that is highly over-expressed in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing cancer cells. Two trials are ongoing with FBP peptides in gynecological cancers: the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial is ongoing in ovarian and endometrial adenocarcinomas (ClinicalTrials.gov Identifier: NCT01580696); the GALE-301 plus GALE-302 Phase 1b clinical trial is ongoing in breast and ovarian cancers (ClinicalTrials.gov Identifier: NCT02019524).

GALE-401 : Phase 2 complete

GALE-401 (Anagrelide Controlled Release) contains the active ingredient anagrelide. The currently available immediate release formulation (Agrylin® or anagrelide IR) is approved by the FDA for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Adverse events associated with anagrelide IR, such as nausea, diarrhea, abdominal pain, palpitations, tachycardia, and headache, may be dose and plasma concentration dependent. Reducing the maximum plasma concentration (Cmax) is expected to reduce side effects, but preserve efficacy. GALE-401 is a reformulated, controlled release version of anagrelide. A Phase 2 pilot study with GALE-401 is ongoing.

MANAGEMENT

Mark W. Schwartz, PhD, *President & CEO*
Bijan Nejadnik, M.D., *EVP and Chief Medical Officer*
Gavin Choy, PharmD, *SVP, Clinical Sciences & Operations*
Patricia Murphy, *VP, Regulatory & Compliance*
Joseph Lasaga, *VP, Business Development & Alliance Management*
John Burns, CPA, *Controller & Principal Accounting Officer*
Thomas Knapp, Esq, *Interim General Counsel*

Immune Pharmaceuticals, Inc.

www.immunepharma.com

CONTACT
Daniel Teper
CEO

ADDRESS
430 East 29th street
Suite 940
New York
10016
USA

TELEPHONE
+1 646 440 9310

SECTOR

- Biotechnology

COMPANY PROFILE

Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's oncology pipeline includes Ceplene®, Azixa® and Crolibulin® as well as bispecific antibodies and nanotherapeutics, including NanomAbs, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. Immune's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. Immune is headquartered in the U.S. (Alexandria Center for Life Science, NY), with its primary R&D facilities in Israel.

PRODUCT PIPELINE

Ceplene / Approved in EU and Israel, Ph3 in US

Ceplene® (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). It has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival while maintaining good quality of life during treatment.

AML patients receive intensive induction treatment with chemotherapeutic drugs at diagnosis, and typically become free of detectable leukemia, achieving "complete remission". However, despite ensuing consolidation therapies, within 1-2 years the majority (75-80%) of adult patients will experience a relapse of leukemia, of which survival prognosis is extremely poor especially in patients over 60 years of age (15-20%). With ~20000 new cases in the US in 2015, poor prognosis following first remission and no other effective remission therapies currently available, AML represents an orphan indication with particularly high unmet need.

Ceplene® acts by enhancing the immunostimulatory effects of IL-2, a T-cell-derived cytokine responsible for activating multiple functions of anti-leukemic T and NK cells. The ability of T and K cells to recognize and eliminate leukemic cells determines the likelihood of maintaining CR in AML. These cells, however, are frequently dysfunctional in AML due to inhibition by myeloid-cell derived reactive oxygen species (ROS). By countering ROS-induced dysfunction and apoptosis of T and NK cells,Ceplene® induces immune-mediated killing of leukemic cells, providing a strong pharmacokinetic rationale for this combination therapy.

A Phase III clinical study of 320 adult patients with acute AML in remission met its primary endpoint of increased leukemia-free survival ($p < 0.01$), indicating that Ceplene® offers an efficacious and tolerable treatment in this population. The absence of treatment-related mortality, combined with the favorable safety profile of Ceplene®, represents a major improvement in the approach to remission maintenance therapy in AML patients. These clinically meaningful, significant results were published in Blood, a leading scientific journal in hematology, (Blood; The Journal of the American Society of Hematology, volume 108, number 1, pp. 88-96, July 1, 2006).

The European Commission has approved Ceplene® for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Ceplene® has been granted orphan drug status for the treatment of AML by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Additional clinical pharmacology and outcomes data in biomarker-defined sub-populations from a post-marketing study conducted in Europe are expected in Q1 2016.

Continued...

Immune Pharmaceuticals, Inc.

www.immunepharma.com

CONTACT
Daniel Teper
CEO

ADDRESS
430 East 29th street
Suite 940
New York
10016
USA

TELEPHONE
+1 646 440 9310

...continued

Nanomabs / Preclinical

Nanomabs are next-generation immune checkpoint-targeted nanoparticles, which contain thousands of cytotoxic molecules and are conjugated to monoclonal antibodies that recognize antigens in order to enhance the nanoparticles' specificity, stability and therapeutic efficacy. The nanoparticle comprises of four modules:

1. **PEGylated polymeric nanoparticles (PPNs)** act as a scaffold, which shields the drug from premature elimination or off-target effects.
2. **Proprietary linker molecules** embedded within the PPN connect the mAb to the rest of the particle.
3. **Anti-cancer drug** (incorporated within the PEGylated polymeric nanoparticles). Several chemotherapeutic drugs with different mechanism of action have been successfully incorporated as lipophilic prodrugs within NanomAbs, e.g. Paclitaxel, Gemcitabine and Oxaliplatin.
4. **Therapeutic mAb** mainly functions as a targeting l igand by binding to a specific tumor antigen.

The Nanomabs platform technology may allow highly targeted delivery of chemotherapeutic agents, thereby decreasing the risk of systemic exposure to these products. Nanomabs targeting capabilities include:

A) **TUMOR TISSUE TARGETING:** NanomAbs preferential uptake into tumor tissue based on the enhanced permeability and retention effect

B) **TUMOR CELL TARGETING:** Active targeting to the receptor by mAb leading to active endocytosis of drug loaded NanomAb

C) **MOLECULAR TARGETING:** Intra-cell delivery of chemotherapeutic (s)

Validation of manufacturing processes and preclinical proof of concept with select immune-oncology targets is expected in 2016.

Bispecific Antibody / Preclinical

Immune has licensed a novel platform for production of tetravalent IgG1-like bispecific antibodies and patents from Atlante Biotech SAS. Company scientists and collaborators created a prototypic bi-specific antibody that retained effector functions and showed mediation of redirected killing of target HLA-DR+ cells by human CD5+ cytokine-induced killer T-cells, demonstrating direct anti-cancer effects in vitro as well as anti-tumor activity and improved survival in vivo in a mouse xenograft model of disseminated leukemia. Results demonstrated alpha-HLA-DR-CD5 bi-specific antibodies mediate chronic lymphoid leukemia (CLL) cell phagocytosis comparable to rituximab (Rituxan®) with potentially less resistance due to greater specificity. Further research will focus on the application of this novel bispecific platform to target immune checkpoints, and Immune's plan is to generate additional preclinical data with selected innovative bispecific drug candidates in 2016, particularly in the immuno-oncology space.

MANAGEMENT

Daniel Teper, *Chief Executive Officer*
Dr. Miri Ben-Ami, *Executive Vice President Oncology, President of Immune Pharma Ltd*
Dr. Monica E. Luchi, *Executive Vice President Global Drug Development, Chief Medical Officer*
G. John Mohr, *Senior Vice President of Business Development*
John Militello, *VP Finance, Contriller, Chief Accounting Officer and Principal Financial Officer*

Immunicum AB

www.immunicum.se

CONTACT
Jamal El-Mosleh, M.Sc.
CEO

ADDRESS
Grafiska vägen 2
SE-412 63 Gothenburg,
Sweden

TELEPHONE
+46 31 41 50 52

EMAIL
info@immunicum.com

YEAR FOUNDED
2002

SECTOR

- Biotechnology

FINANCIAL SUMMARY

Ongoing fully underwritter rights issue of about USD 13 million and an upcoming directed issue to institutional investors of USD 13 million.

Listed on NASDAQ OMX First North Premier in Sweden with a market cap of USD 66 million. Listing on main market (Small Cap) later in 2016.

COMPANY PROFILE

PROMISING CLINICAL DATA

Our main product, INTUVAX, an off-the-shelf cellbased product for personalized treatment, has been evaluated in a finalized clinical Phase I/II-study in metastatic renal cell carcinoma with promising follow up data showing a massive intratumoral infiltration of CD8+ T cells in the majority of treated patients and a more than double ongoing median overall survival for the whole group (11 patients) and more than tripple prolonged and ongoing median overall survival for patients with poor prognosis (6 patients). A clinical phase II-trial (90 parients) is currently being performed in Europe and will be expanded into the US in 2016. Prelmininary data on intratumoralinfiltration of CD8+ T cells indicate tumor specific immune response. We are also finalizing a clinical Phase I/II-study in primary liver cancer, so far showing clear indications of tumor specific immune responses that directly correlate with prolonged survival for the majority of fully treated patients (9). Our goal is to provide cancer patients with treatments that improve both survival and quality of life. Our research is based on platform technologies, enabling us to develop immune enhancers against a wide spectrum of cancer types.

PHASE II TRIALS AND LICENSING

Our aim is to advance therapeutic cancer treatments at least through clinical phase II-trials. We intend to out-license product candidates to pharmaceutical/ biotech companies investing in the field of immunotherapies against cancer.

PRODUCT PIPELINE

IINTUVAX

INTUVAX is based on specially prepared allogeneic dendritic cells, un-loaded with tumor antigens, for intratumoral injection.

INTUVAX-cells are not used as antigen-presenting-cells, but as a vaccine adjuvant, using the patients' own tumors as antigen sources for direct access to neo-antigens.

INTUVAX is an off-the-shelf product for personalized treatment.

INTUVAX is currently being tested in a phase II-trial in combination with Sunitinib for treatment of metastasized renal cell carcinoma.

INVESTMENT & LICENSING OPPORTUNITIES

INTUVAX

Immunicum is looking to out-license INTUVAX to larger biotech and/or pharmaceutical companies.

Investment in Immunicum

Immunicum is looking for larger institutional investors to participate in the upcoming directed issue totaling USD 13 million.

MANAGEMENT

Jamal El-Mosleh, M.Sc., *CEO*

JW Pharmaceutical Corporation

www.cwp.co.kr/pharma/en/intro/pharma.jsp

CONTACTS

Zi-Ho Yeom
Vice President, Business Development & Licensing

Jason Youngmin Park
Manager, Business Development & Licensing

ADDRESS
2477, Nambusunhwan-ro,
Seocho-gu,
Seoul, 137-864,
Korea

TELEPHONE
+82 2 840 6777

YEAR FOUNDED
1945

SECTOR

- Biotechnology

COMPANY PROFILE

JW Pharmaceutical Corporation (formerly Choongwae Pharma.) is one of the leading pharmaceutical companies in Korea.

JW is currently exploring early stage oncology R&D via a collaborative effort between the JW Drug Discovery Center in Korea and the JW Theriac Corp in Seattle in the US. This early R&D activity is facilitated by internally developed platform technologies that led to the targeted approach being used for oncology indications. Our oncology pipeline of product candidates is led by CWP291, the First-In-Class Wnt Signaling Inhibitor currently in phase I study in US and Korea for Acute Myeloid Leukemia and Multiple Myeloma.

MANAGEMENT

Zi-Ho Yeom, *Vice President, Business Development & Licensing*
Jason Youngmin Park, *Manager, Business Development & Licensing*

MaxCyte, Inc.

www.maxcyte.com

CONTACT
Dr. Madhusudan Peshwa
CSO and EVP, Cellular Therapies

ADDRESS
22 Firstfield Road, Suite 110
Gaithersburg,
MD 20878
USA

TELEPHONE
+1 301 944-1700

EMAIL
info@maxcyte.com

YEAR FOUNDED
1998

SECTOR

- Biotechnology

COMPANY PROFILE

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers with an established regulatory path.

MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies in a number of cancer indications, including solid tumors.

MANAGEMENT

Dr. Madhusudan Peshwa, *CSO and EVP, Cellular Therapies*

Memgen, LLC

www.memgenbio.com

CONTACTS

Robert Coates
Chief Executive Officer

Mark Cantwell
Chief Scientific Officer

ADDRESS

12 Greenway Plaza
Suite 1100
Houston, TX 77046
USA

EMAIL

bizdev@memgenbio.com

YEAR FOUNDED

2004

SECTOR

- Biotechnology

COMPANY PROFILE

Memgen is a clinical-stage biotech company who's lead product, ISF35, is a first-in-class viral cancer immunotherapy encoding an optimized version of CD40 ligand.

Memgen's ISF35 viral cancer immunotherapy is being combined with checkpoint inhibitors to potentially treat a broad range of cancer types, including but not limited to metastatic melanoma, bladder cancer, renal cell cancer and hepatocellular carcinoma.

Memgen will be presenting an update on ISF35. Topics to be covered include:

1. Pre-clinical data by MD Anderson showing that ISF35 in combination with checkpoint inhibitors cures 40% of mice in a B16 model of metastatic melanoma and eradicates melanoma in the brain.
2. Phase 1/2 study protocol by MD Anderson of ISF35 plus KEYTRUDA in checkpoint inhibitor refractory metastatic melanoma.
3. Phase 2 study protocols at MD Anderson of ISF35 with OPDIVO for metastatic renal cell carcinoma.
4. Orphan drug designation of ISF35 for advanced melanoma.

PRODUCT PIPELINE

ISF35 : Clinical Phase 2

ISF35 is a viral cancer immunotherapy encoding an optimized version of CD40 ligand.

ISF35 is being combined with checkpoint inhibitors to potentially treat a broad range of cancer types, including but not limited to metastatic melanoma, bladder cancer, renal cell cancer and hepatocellular carcinoma.

MANAGEMENT

Robert Coates, *Chief Executive Officer*
Mark Cantwell, *Chief Scientific Officer*

Merrimack Pharmaceuticals, Inc.

www.merrimack.com

CONTACTS

Dr. Birgit Schoeberl
Head of Discovery

Dr. Yasir Al-Wakeel
Chief Financial Officer and Head of Corporate Development

ADDRESS

One Kendall Square,
Suite B7201
Cambridge, MA 02139
USA

TELEPHONE

+1 617 441 1000

EMAIL

info@merrimack.com

SECTOR

- Biotechnology

COMPANY PROFILE

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA in October 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

MANAGEMENT

Robert J. Mulroy, *President and Chief Executive Officer*
Dr. Yasir Al-Wakeel, *Chief Financial Officer, Head of Corporate Development*
Kathleen P. Gallagher, *Chief of Staff, Head of Corporate Communications*
Peter N. Laivins, *Head of Development*
Gavin MacBeath, Ph.D., *Founder, Head of Translational Medicine*
William M. McClements, *Head of Corporate Operations*
Jeffrey A. Munsie, *General Counsel, Head of Compliance, and Secretary*
Dr. Birgit Schoeberl, *Head of Discovery*
Edward J. Stewart, *Head of Commercial*

Mirna Therapeutics, Inc.

www.mirnatherapeutics.com

CONTACTS

Casi DeYoung MBA
Chief Business Officer

Vincent O'Neil MD
Chief Medical Officer

ADDRESS
2150 Woodward St.,
Suite 100
Austin, TX 78744
USA

TELEPHONE
+1 512 901 0900

EMAIL
info@mirnarx.com
busdev@mirnarx.com

YEAR FOUNDED
2007

SECTOR

- Biotechnology

COMPANY PROFILE

Mirna's lead product candidate, MRX34, is the first microRNA mimic to enter clinical development and has demonstrated multiple confirmed responses as a single agent in our ongoing Phase 1 clinical trial. MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. MRX34 entered clinical testing in 2013 and is being studied in a multicenter Phase 1 trial in patients with primary liver cancer, other solid cancers, and hematological malignancies.

We believe microRNA Replacement Therapy restores the body's natural ability to fight cancer on multiple levels, including repression of tumor immune evasion, tumor growth, cancer stem cells and metastasis, by replacing naturally occurring tumor suppressor microRNAs that are under expressed in cancer cells with microRNA mimics. We believe controlling these multiple cancer pathways may also reduce the risk of the development of drug resistance, one of the more prevalent problems of modern cancer therapies.

Our pipeline is based on microRNAs. We believe tumor suppressor microRNA mimics have potential as cancer therapeutics due to their capacity to regulate many different oncogenes across multiple pathways, as compared to other targeted cancer therapies that affect only one or two oncogenes or oncogenic pathways. Some of these miRNA mimics may also repress checkpoint signaling molecules to inhibit tumor evasion pathways. We have identified multiple tumor suppressor microRNAs that have demonstrated the ability to inhibit cancer cell proliferation and tumor growth in preclinical studies. Each tumor suppressor miRNA regulates a unique set of genes and oncogenic pathways that we believe will enable the development of multiple therapeutic candidates either as monotherapies or as combination therapies.

Mirna's owned and in-licensed intellectual property portfolio includes at least 10 issued U.S. patents and more than 42 pending U.S. and foreign applications.

Mirna Therapeutics was founded in 2007 and is located in Austin, Texas.

MANAGEMENT

Paul Lammers, MD, MSc, *President & Chief Executive Officer*
Miguel Barbosa PHD, *Chief Scientific Officer*
Vincent O'Neil MD, *Chief Medical Officer*
Casi DeYoung MBA, *Chief Business Officer*
Alan Fuhrman, *Chief Financial Officer*
Andreas Bader, PhD, MS, *Vice President Translational Research & Developement*
David Brown, PhD, *Vice President Preclinical Pharmacology*
John Irvin, *Vice President Finance*
Neil Leatherbury MS, *Director, Pharmaceutical Development*
Jay Stoudemire, PhD, *Vice President Preclinical Development, Regulatory & Quality Assurance*

Nanobiotix SA

www.nanobiotix.com

CONTACT
Bernd Mühlenweg
Chief Business Officer

ADDRESS
60 rue de Wattignies
Bat B
75012 Paris
France

TELEPHONE
+33 0 1 40 26 04 44

YEAR FOUNDED
2003

SECTOR

- Biotechnology

COMPANY PROFILE

Nanobiotix, pioneer and leader in nanomedicine has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: nanoparticles interact with X-rays and maximize the effect of radiotherapy within tumor cells. NanoXray products enhance the radiotherapy efficacy in the tumor without increasing healthy tissues damages. NanoXray products are built on the existing standard of care and can be used with every existing radiation equipment available in almost every hospital world-wide. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo and was incorporated in 2003. Nanobiotix has been primarily funded by leading European venture capital firms. The company has about 40 employees. Nanobiotix is based in Paris, France and has announced on September 22th, 2014 the opening of its first US office in Boston, Massachusetts.Nanobiotix's objective is to enhance its leading position in the nanomedicine field and to develop a meaningful and effective cancer treatment. With the NanoXray products the major cancers indications can be targeted (breast cancer, prostate cancer, lung cancer…) showing its huge market potential. Thanks to the physical based mechanism of action of its nanoparticles, Nanobiotix operates a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

MANAGEMENT

Laurent Levy, PhD, *Chief Executive Officer*
Elsa Borghi, MD, *Chief Medical Officer*
Philippe Mauberna, *Chief Financial Officer*
Bernd Muehlenweg, *Chief Business Officer*

Oncology Venture

www.oncologyventure.com

CONTACTS
Peter Buhl Jensen
CEO & Founder

Ulla Hald Buhl
COO & Founder

ADDRESS
Venlighedsvej 1
DK-2970
Hoersholm
Denmark

TELEPHONE
+45 21 70 10 49

EMAIL
pbj@oncologyventure.com
uhb@oncologyventure.com

YEAR FOUNDED
2012

SECTOR

• Investor - Other • Pharmaceuticals/Licensing

COMPANY PROFILE

Oncology Venture is attending SACHS ASSOCIATES Immuno-oncology BD&L investment Forum, with the goal of discussing partnering and investment into our immuno-oncology MegaFAS-Ligand (APO010) a Phase 2 ready drug asset (summary below).

Oncology Venture utilize the validated and proprietary gene-tumor DRP™-technology to select the high likely responding patients in order to accelerate oncology drugs to a (breaktrough) designation.

We are pursuing a precision medicine strategy to drug development and would be pleased to meet with you to tell you more about our drug-asset(s) and business model.

PRODUCT PIPELINE

APO010, Phase 2 ready

Immuno-Oncology Drug with Unique MoA
APO010 is a multimeric form of FAS-ligand for immuno oncology therapy. APO010 acts through the FAS receptor leading to apoptosis of the malignant cells. APO010 is expected to act in synergy with other immuno oncology agents.

Clinical Data Phase 1
A dose escalation phase 1 study has previously been conducted, including 26 patients. In this study, maximum-tolerated dose was not reached.

Drug Response Predictor – DRP™
For enrichment of patient population, APO010 is complemented by our DRP™ companion diagnostic technology -APO010 DRP™.

Clinical Development Plan:
Pre-clinical studies have shown APO010 to be highly efficient in Multiple Myeloma (MM). Therefore, a focused phase 1b/2 trial will be conducted with MM patients, pre-screened for sensitivity using APO010 DRP™ technology.

Market Potential:
There is great demand for effective treatments of Multiple Myeloma, and the market value during 2014 was over 7 billion USD. Researchers estimate the cancer immunotherapy market to USD 35 billion by 2023 (Citi GPS).

MANAGEMENT

Peter Buhl Jensen, *CEO & Founder*
Ulla Hald Buhl, *COO & Founder*
Steen Knudsen, *CSO, Co-Founder*
Nikolaj Buhl Jensen, *CFO*
Annie Rasmussen, *COO*
Daniel Von Hoff, *Medical Advisor*

OncoSec Medical, Inc.

www.oncosec.com

CONTACT
Punit Dhillon
Chief Executive Officer

ADDRESS
5820 Nancy Ridge Drive,
San Diego, CA 92121
USA

TELEPHONE
+1 858 662 6732

EMAIL
investors@oncosec.com

YEAR FOUNDED
2011

SECTOR

- Biotechnology

COMPANY PROFILE

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in clinical development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com

PRODUCT PIPELINE

ImmunoPulse : Phase II Clinical Development
ImmunoPulse™ is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of ImmunoPulse™ with DNA-based IL-12 demonstrated the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. This technology employs electroporation, which involves the use of electrical pulses to increase the permeability of the cell membrane, permitting the DNA to enter the cells.

MANAGEMENT

Punit Dhillon, *Chief Executive Officer*
Richard B. Slansky, *Chief Financial Officer*
Robert H. Pierce, M.D., *Chief Scientific Officer*
Sheela Mohan-Peterson, *Chief Legal and Compliance Officer*

OSE Immunotherapeutics

www.osepharma.com

CONTACTS
Dominique Costantini
CEO

Alexis Peyroles
COO / Finance and BD

ADDRESS
Pépinière Paris Santé Cochin
29 bis rue du Faubourg Saint Jacques
75014 Paris
France

TELEPHONE
+33 0 1 43 29 78 57

EMAIL
info@osepharma.com

YEAR FOUNDED
2012

SECTOR

- Biotechnology

COMPANY PROFILE

OSE Immunotherapeutics results from the merger between Effimune and OSE Pharma (May 31, 2016). The combined company is a new international player in immunotherapy. It offers innovative immunotherapies based on the activation and the regulation of the immune system, with clinical applications in immuno-oncology, auto-immunity and transplantation. Tedopi®, a specific T immunotherapy that activates cytotoxic T lymphocytes and targets patients with Non-Small Cell Lung Cancer (NSCLC) and who are HLA-A2 positive. o Tedopi® is currently in Phase 3 registration clinical trial for lung cancer in Europe and in the USA; trial completion is expected in 2018. o A Phase 2 clinical trial of Tedopi® combined with a checkpoint inhibitor is considered for lung cancer in 2017, in partnership with a European research organization. o New indications for other cancers involving a strong medical need are considered with industrial partners. Tedopi® is open for partnership on Territories and co-development. Effi-DEM, is being developed for immuno-oncology. It is a second generation checkpoint inhibitor. It targets particular suppressor cells present in the tumor microenvironment, associated with a poor prognosis. They are myeloid-derived suppressor cells (MDSC) and macrophage cells associated with tumors called "Tumor Associated Macrophages" or TAM. TAM cells are a major part of the tumor microenvironment in the case of aggressive tumors and are linked to malignant progression. FR-104 is in a Phase 1 clinical trial : a CD-28 antagonist, optimized monoclonal antibody fragment targeting the CD-28 receptor, a key receptor in effector T lymphocytes. Janssen Biotech (a subsidiary of Johnson & Johnson) has an option on licensing the full rights for this product after the phase 1. Another asset available for partnering is Effi-7 targeting CD127 (alpha chain of the Interleukin-7 receptor) with comprehensive pre-clinical data in various auto-immune disease models and a first clinical focus in ulcerative colitis. The new combined entity OSE Immunotherapeutics will build together a significant immunotherapy player focused on Immune Activation and Regulation.

PRODUCT PIPELINE

Tedopi
Tedopi®, a specific T immunotherapy that activates cytotoxic T lymphocytes and targets patients with Non-Small Cell Lung Cancer (NSCLC) and who are HLA-A2 positive.

- Tedopi® is currently in Phase 3 registration clinical trial for lung cancer in Europe and in the USA; trial completion is expected in 2018.
- A Phase 2 clinical trial of Tedopi® combined with a checkpoint inhibitor is considered for lung cancer in 2017, in partnership with a European research organization.
- New indications for other cancers involving a strong medical need are considered with industrial partners.

Tedopi® is open for partnership on Territories and co-development.

Effi-DEM : Preclinical
Effi-DEM, is being developed for immuno-oncology. It is a second generation checkpoint inhibitor. It targets particular suppressor cells present in the tumor microenvironment, associated with a poor prognosis. They are myeloid-derived suppressor cells (MDSC) and macrophage cells associated with tumors called "Tumor Associated Macrophages" or TAM. TAM cells are a major part of the tumor microenvironment in the case of aggressive tumors and are linked to malignant progression.

MANAGEMENT

Dominique Costantini, *CEO*
Alexis Peyroles, *COO / Finance and BD*

UbiVac

www.ubivac.com

CONTACT
Dr. Bernard Fox
President & Chief Executive Officer

ADDRESS
4805 NE Glisan
2N56 North Pavilion
Providence Cancer Center
Portland, OR 97213
USA

TELEPHONE
+1 503 215 3769

EMAIL
info@ubivac.com

SECTOR

- Biotechnology

COMPANY PROFILE

UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer and infectious diseases. UbiVac is a company that offers a pipeline of groundbreaking immunotherapies in preclinical and clinical stage trials. Since 2005 the company has been engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases.

MANAGEMENT

Dr. Bernard A Fox, PhD, *President & Chief Executive Officer*
Dr. Hong-Ming Hu, PhD, *Chief Scientific Officer*
Mr. Bernard A Fox III, *Chief Financial & Operating Officer*
Dr. Traci Hilton, PhD, *Vice President Vaccine Development*

Silver Sponsor

Roche

www.roche.com

We have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.

Supporters

BIO Deutschland

www.biodeutschland.org

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector.

The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises.

BIO Deutschland is Germany's biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.

Supporters

Biotech Gate

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries.

There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

Supporters

Citigate Dewe Rogerson

Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world's leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo – NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m).
Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A).
Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

Supporters

Edison

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington.

It employs more than 70 equity analysts operating from offices in London, New York, Sydney, Wellington and Frankfurt that provides research coverage on more than 700 publicly traded companies, making it one of the largest dedicated small and mid-cap research providers worldwide. Healthcare is the largest industry group within Edison with 12 analysts covering some 150 biotech/medical device companies located in UK, Continental Europe, North America and Australia.

Supporters

FreeMind

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources.

Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind's knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Supporters

INSTINCTIF PARTNERS

Instinctif Partners

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy.

With a **track record** of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering **specialist expertise** seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities.

Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our **globally integrated** and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.

Supporters

One Nucleus

www.onenucleus.com

One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe's largest life science and healthcare cluster.

Organisation History

Established in 1997, One Nucleus is a **not-for-profit** membership organisation located in Cambridge. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus' mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people's lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients.

Supporters

Swiss Biotech Association

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area).

The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland's profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.Swiss Biotechs' mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry.

The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Supporters

Tiberend Strategic Advisors, Inc.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics.

We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

Organisers

SACHS ASSOCIATES

Sachs Associates

www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on bio-pharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Online One-to-One Meeting System
In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online one to one meeting system, allowing you to set up, accept or decline private one to one meetings with other conference attendees. These meetings are scheduled at your convenience in private meeting rooms and last 30 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

Cutting edge Content with Eminent Speakers
Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior scientific and business personalities as speakers at its events.

Sponsorship and Marketing Opportunities for forthcoming events
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your position your company in this market.

Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:

- Conference Sponsor – including workshops and social events
- Exhibition stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com

We look forward to seeing you at:

4th Annual

MedTech & Digital Health Forum

For Technology & Healthcare Innovation

26th September 2016 • Congress Center Basel • Switzerland

16th Annual

Biotech in Europe Forum

For Global Partnering & Investment

27th – 28th September 2016 • Congress Center Basel • Switzerland

For more information about all our events please visit **www.sachsforum.com**

SACHS ASSOCIATES

27 Belsize Lane
London NW3 5AS

Tel: +44 (0)203 463 4890
Fax: +44 (0)207 691 7919

Follow us on Twitter – @SachsAssociates

www.sachsforum.com